Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS
Document Type and Number:
WIPO Patent Application WO/2018/068010
Kind Code:
A1
Abstract:
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are dessorbed and pharmaceutical compositions comprising at least one of the same.

Inventors:
MAGNANI JOHN L (US)
PETERSON JOHN M (US)
BAEK MYUNG-GI (US)
Application Number:
PCT/US2017/055648
Publication Date:
April 12, 2018
Filing Date:
October 06, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
GLYCOMIMETICS INC (US)
International Classes:
A61K47/60; A61P35/00; C07H15/207; C07H15/26
Domestic Patent References:
WO2014070991A22014-05-08
WO2008060378A22008-05-22
WO2013096926A12013-06-27
WO2013090926A12013-06-20
Foreign References:
USRE44778E2014-02-25
Other References:
THOMA G ET AL: "Nanomolar E-selectin inhibitors: 700-fold potentiation of affinity by multivalent ligand presentation", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, US, vol. 123, no. 41, 17 October 2001 (2001-10-17), pages 10113 - 10114, XP002510185, ISSN: 0002-7863, [retrieved on 20010922], DOI: 10.1021/JA0164430
HIGUCHI, T. ET AL.: "Pro drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
EDWARD B. ROCHE: "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
"Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th ed.", December 2000, WILEY
GREEN, T. W.; P.G.M. WUTZ: "Protective Groups in Organic Synthesis, 3rd ed.", 1999, WILEY
P. H. STAHL; C. G. WERMUTH: "Handbook of Pharmaceutical Salts", 2002, VERLAG HELVETICA CHIMICA ACTA
"Synthetic Organic Chemistry", JOHN WILEY & SONS, INC.
S. R. SANDLER ET AL.: "Organic Functional Group Preparations, 2nd ed.", 1983, ACADEMIC PRESS
H. O. HOUSE: "Modem Synthetic Reactions, 2nd ed.", 1972, W. A. BENJAMIN, INC.
T. L. GILCHRIST: "Heterocyclic Chemistry, 2nd ed.", 1992, JOHN WILEY & SONS
J. MARCH: "Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th ed.", 1992, WILEY-INTERSCIENCE
FUHRHOP, J.; PENZLIN G.: "Organic Synthesis: Concepts, Methods, Starting Materials, Second, Revised and Enlarged Edition", 1994, JOHN WILEY & SONS, ISBN: 3-527-29074-5
HOFFMAN, R.V: "Organic Chemistry, An Intermediate Text", 1996, OXFORD UNIVERSITY PRESS, ISBN: 0-19-509618-5
LAROCK, R. C.: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd ed.", 1999, WILEY- VCH, ISBN: 0-471-19031-4
MARCH, J.: "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 4th ed", 1992, JOHN WILEY & SONS, ISBN: 0-471-60180-2
OTERA, J.: "Modem Carbonyl Chemistry", 2000, WILEY-VCH
PATAI, S.: "Patai's 1992 Guide to the Chemistry of Functional Groups", 1992, INTERSCIENCE, ISBN: 0-471-93022-9
QUIN, L.D. ET AL.: "A Guide to Organophosphorus Chemistry", 2000, WILEY-LNTERSCIENCE, ISBN: 0-471-31824-8
SOLOMONS, T. W. G.: "Organic Chemistry, 7th ed.", 2000, JOHN WILEY & SONS, ISBN: 0-471-19095-0
STOWELL, J.C.: "Intermediate Organic Chemistry, 2nd ed.", 1993, WILEY-INTERSCIENCE, ISBN: 0-471-57456-2
"Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia", 1999, JOHN WILEY & SONS, ISBN: 3-527-29645-X
"Organic Reactions", 1942, JOHN WILEY & SONS
.: "Chemistry of Functional Groups", JOHN WILEY & SONS
DEWEERDT., NATURE, vol. 480, 14 December 2011 (2011-12-14), pages S38 - S39
MITSIADES ET AL., CLIN. CANCER RES., vol. 15, 2009, pages 1210021
ZUBER ET AL., GENES DEV., vol. 23, no. 7, 1 April 2009 (2009-04-01), pages 877 - 889
KIEL ET AL., CELL, vol. 121, 2005, pages 1109 - 21
SUGIYAMA, IMMUNITY, vol. 25, 2006, pages 977 - 88
MENDEZ-FERRER ET AL., NATURE, vol. 466, 2010, pages 829 - 34
BUTLER ET AL., CELL STEM CELL, vol. 6, 2010, pages 251 - 64
WINKLER ET AL., NATURE MEDICINE, 21 October 2012 (2012-10-21)
ALESSANDRO, INI. J. CANCER, vol. 121, 2007, pages 528 - 535
ZHENG ET AL., WORLD J. GASTROENTEROL., vol. 7, 2001, pages 431 - 434
UENO ET AL., BLOOD, vol. 102, 2003, pages 3829 - 36
MIMEAULT ET AL., CLIN. PHARMACOL. THERAPEUTICS, vol. 82, 2007, pages 252 - 64
PELUS, CURR. OPIN. HEMATOL., vol. 15, 2008, pages 285 - 92
LEMOLI ET AL., HAEMATOLOGICA, vol. 93, 2008, pages 321 - 24
GENNARO: "Remington: The Science and Practice of Pharmacy, 21st ed.", vol. 21, 2005, MACK PUB. CO
A. F. KYDONIEUS: "Transdermal Delivery of Drugs", 1987, CRL PRESS
SMITH ET AL.: "Percutaneous Penetration Enhancers", 1995, CRC PRESS
LENNERAS ET AL., J. PHARM. PHARMACOL., vol. 54, 2002, pages 499 - 508
KARANDE ET AL., PHARM. RES., vol. 19, 2002, pages 655 - 60
VADDI ET AL., INT. J. PHARM., vol. 91, 2002, pages 1639 - 51
VENTURA, J. DRUG TARGET, vol. 9, 2001, pages 379 - 93
SHOKRI ET AL., INT. J. PHARM., vol. 228, no. 1-2, 2001, pages 99 - 107
SUZUKI ET AL., BIOL. PHARM. BULL., vol. 24, 2001, pages 698 - 700
ALBERTI ET AL., J. CONTROL RELEASE, vol. 71, 2001, pages 319 - 27
GOLDSTEIN ET AL., UROLOGY, vol. 57, 2001, pages 301 - 5
KIIJAVAINEN ET AL., EUR. J. PHARM. SCI., vol. 10, 2000, pages 97 - 102
TENJARLA ET AL., INT. J. PHARM., vol. 192, 1999, pages 147 - 58
Attorney, Agent or Firm:
CHAPMAN, Ernest F. et al. (US)
Download PDF:
Claims:
What is claimed is:

1 , At feast one compound chosen, from glyeooiinietk E-selectin antagonists of Formula 0):

m

prodrugs of Formula (I), aad pharmaceutically acceptable sails of any of the foregoing, wherein

each Rf , which may be identical or different, is independently chosen from H, C\. alfcyl , CMS aikenyi, G: ^al « L..and -NH O^R* groups, wherein each R3, which may he identical or different, is independently chosen from CM? aJkyl, Ci-n alkenyl, CJ-SS alkynyl, Ci.is aryl, and CMS heteroaryi groups;

each ", which may be identical or different, is independently chose from halo, -

GY\

-NY ' Ύ2, -OC(=0) ' s ~ΝΗ0(=Ο)Υ ' , and. ~MHC(=0) Y! Y '2 groups, wherein each Y! and each V, which may he identical or different, are independently chosen from H, C ^ alkyJ, -t-12 alkenyl€2-12 alkynyl C1.12 hsloalkyl, C i haloalkenyi, C2.11 haloalkynyl. CMS atyi, and CMS heteroaryi groups, wherein Y1 and Y;' may join together along with the nitrogen atom to which they are attached to form a ring

each R\ which may be identical or different, is independently chosen from

wherein each R", which may e identical or different, is independently chosen irom H, O-12 alky! and CM;; haioalkyl groups, and wherein each R ', which may be identical or different, is independently chosen from C alkyl, C?.s aikeny!, Cj,g alkynyl, -OY'\ -NHGH, -NHOCHs, -NHC f, and -ΝΥ'Ύ4 groups, wherein each Y'5 and each Y4, which may be identical or different, are independently chosen irom B,.CM alkyl, C¾-& alkenyl. C alkynyl, C ¾ haioalkyl, (¾.s haloalkenyi, and (¾.s haloalkynyl groups, wherein Y' and Y4 may join together along with the nitrogen atom to which they are attached to form a ring;

each R4, which may be identical or different, is independently chosen from -CN, Cut alkyl, and CM haioalkyl groups;

m is chosen from integers ranging from 2 to 256; and

L is chosen from linker groups;

wwiitthh tthhee pprroovviissoo tthhaatt when m is 4, each R! and each R4 is methyl, each R'; is •~OC(=0)Ph, and eac R* is

then the linker groups are not chosen from

2. The at least one compound according to 'claim I , with the rov so that when m is 4, each R5 and each R4 is methyl, each R~ is ~0C(!O)Ph, and each R* is

then the linker groups are not chosen from

wherein p is chosen from integers ranging from © to 250.

3. The at least one compound according to claim 1 or claim 2, wherein at ieast one R! is H.

4. The at least one compound according to claim 1 or claim 2, wherein at Ieast one R* is

3. The at least one compound according to claim 1 or claim 2, wherein at Ieast one R ethyl.

6. The at least one compound according to claim 1 or claim 2, wherein at ieast one R chosen from -NHC(::::0)R5 groups,

?. The at least one compound according to claim 6, wherein al least one R5 is chosen from

- ios -

groups, wherein each Z is independently chosen H„ -OH, 0, F, ]% -Ni¾, Cj-ssikyl, C-2-8 aJkenyl, CM alkynyl, C¼.H aryi, -OC-j-« all y!, -OC2 afkenyl, -OCj-g alkynyl, nd -OC^ aryl groups, wherein is chosen frora integers ranging from 0 to 3.

8. The at feast one compound according any proceeding claim, wherein at least one R2 is H.

9. The at feast ooe comp und according to any one of claims 1-7, wherein a least one R2 is F.

10. The at feast one compound according to any one of claims 1-7, wherein at least, one R2 is CL

11. The at least one compound according to any one of claims 1-7, wherein at least, one R2 is chosen from -OY! . 12, The at least one compound according to any one of claims i-7. wherein at least one R? is chosen 1τοηι ~00(=0)Υ!.

13, The at least one compound according to any one of claims 1-7, wherein at least one

R2 is chosen ftotn-NY^'2.

14, The at least one compound according to any one of claims 1-7, wherein at least one R3 is chosea from ~NH(Css )Y5.

15, The at least one compound according to any one of claims i -7, wherein at least one R - is chosen ftom -NHiC^OjNY'Y3.

16, The at least one compound according to claim 11 , claim 13, or claim 15, wherein at least one of Yf and Y' is H.

I?. The at least one compound according to claim 11, claim 13, or claim 15, wherein each of Y3 and Y2 is H.

18. The at least one compound according to any one of claims 11-16, wherein

Υ' is methyl,

1 . The at least one compound according to any one of claims 1 - Ϊ 6, wherein

Y! is phenyl.

20. The at least one compound according to any one of claims 1-7, wherein at least one R- is chosen from

21. The at least one compound according to any proceeding claim, wherein at least one R'" is chosen from

22, The at least one compound according to any one of claims i -21, wherein at least one J is chosen from

25. The at least one compound according to claim 23, wherein at least one R'1 is chose from

26. The at least one compound according to any proceeding claim, wherein at least one R'" is -OH.

27. The a t least one compound according to any one of claims 1-26, wherein at least one ; is chosen fro

28. The at least one compound according to claim 27, wherein at least one R is chosen from

29. The at least one compound accordin to any proceeding claim, wherein at least one R4 is CH5

30, The ai least one compound according to any one of claims 1-28, wherein at least one R4 is chosen from C¾F, CH j, and (.¾.

31 , The at least one compound according to any one of claims 1-30, wherein at least one R4 is CF¾.

32, The at least one compound according to claim J or claim 2, wherein the compound is chosen from compounds having the following Formula:

3. The at least otte compound according to claim 1 or claim 2, wherein the 'compound is lios n from compounds having the following Formula:

34. The at least one compound according to claim I or claim 2, wherein the compound is chosen from compounds having the following Formula;

35, The at least one compound according to claim 1 or claim 2, wherein (he compound is chosen from compounds having the following Formula:

36. The .si least one compound according to any preceeding claim, wherein m is chosen from integers ranging from 2 to N.

37. The at least one compound according to claim 36, wherein m is chosen from integers ranging from 2 to 4,

38. The at least one compound according to claim 36, wherein m is 4.

39. The at least one compound according to claim 36, wherein m is 3.

40. The at least one compound according to claim 36, wherein m is 2.

41. The at least one compound according to any one of claims 1-39, wherein L is a dendrimer.

42„ The at least one compound : accordin to an one of claims 1 -40, wherein L is a chosen ftotn

wherein Q is a chosen from

wherein & is chosen from H, O-salkyi, Ce-jg aryl, C7.jsary1aikyi, and CM* heteroar l groups and each p, which may he identical or different, is independently chosen from inlegers ranging from 0 to 250.

43. The at least one compound according to claim 42, wherein R* is H.

44. The at least, one compound according to claim 42, wherein h is benzyl

45. The at least one compound according to any one of claims 42-44, wherein p is chosen from integers ranging from is 0 to 30.

46. The at least one compound according to claim 45, wherein p is 5.

47. The at least one compound according to claim 45, wherein p is 4,

48. The at least one compound according to claim 45, wherein p is 3.

49. The at least one compound according to claim 45, wherein p is 2.

50. The at least one compound according to claim 45, wherein, p is 3.

51. The at least one compound according to claim 45, wherein p is 0.

52. The at least one compound according to any preceeding claim, wherein the compound- is symmetrical,

53. A composition comprising at least one compound according to any preceeding claim and at least one additional pharmaceutically acceptable ingredient.

54. A method for treatment and/or prevention of at feast one disease, disorder, and/or condition where inhibition of'E-selecrm mediated functions is useful the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1 -52.

55. A method for treatment and/or prevention of at least one mflan¾»aiory disease, disorder, and/or condition, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-52 ,

56. A method for treatment and/or prevention of metastasis of cancer ceils, the method comprising.administering to a subject i need thereof an effective amount of at least one com ound of any one of claims 1-52.

57. A method for inhibiting infiltration of cancer cells into hone marrow, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-52.

58. A method for inhibiting adhesion of a tumor ceil that expresses a iigand of E-seleetin to an endothelial cell expressing E-selectin, the method comprising contacting the endothelial cell with an effective amount of at least one compound of any one of claims 1-52.

59. The method according to claim 58, wherein the endothelial eel! is present in bone marrow.

60. A method for treatment and/or prevention of thrombosis, the method comprising administering to a subject in need thereof an effective- mount of at least one compound of arty one of claims 1-52.

61. A method for treatment -and/or prevention of cancer, the method comprising administering to a subject in need thereof fa) an effective amount of at least one compound of any one of claims 1-52 and (h) at least one of therapy chosen from (i) chemotherapy and (ii) radiotherapy.

62. A method for enhancing hematopoietic stem cell survival, the method comprising administering to a subject in need {hereof an effective amount of at least one compound of any one of claims 1-52.

63. The method according to claim 62, wherein the subject has cancer and has received or will receive chemotherapy and/or radiotherapy,

64. A method for treatment and/or prevention of mucositis, the met hod comprising administering to a sabjeci in need thereof an effective amount of at least one compound of any one of claims 1-52,

65. The method according to claim 64, wherein the mucositis is oral mucositis, esophageal mucositis, and/or gastrointestinal mucositis,

66. The method according to claim 64, wherei the subject is afflicted with head and neck, breast, lung, ovarian, prostate, lymphatic, leukemic, and or gastrointestinal cancer.

67. A method for mobilizing cells from the bone marrow, the method comprising administering to a subject in need thereof an effecti ve amount of at least one compound of any one .of claims 1 -52.

'68. The method according to claim 67, wherein the cells are hematopoietic ceils and/or tumor cells.

AMENDED CLAIMS

received by the International Bureau on 01 March 2018 (01.03.2018)

1. At least one compound chosen from glycomimetic E-selectin antagonists of Formula

(I):

(I)

prodrugs of Formula (1), and pharmaceutically acceptable salts of any of the foregoing, wherein

each R1 , which may be identical or different, is independently chosen from H, C .n alkyl , C2_i2 alkenyl, C2-i2 alkynyl, and -NHC(=0)R5 groups, wherein each R5, which may be identical or different, is independently chosen from CM2 alkyl, C2-12 alkenyl, C2_i2 alkynyl, C6-18 aryl, and Cj.n heteroaryl groups;

each R2, which may be identical or different, is independently chosen from halo, - OY1 , -ΝΥ'Υ2, -OC^C Y1, -NHC(=0)Y1, and -NHC(=0)NY'Y2 groups, wherein each Y1 and each Y2, which may be identical or different, are independently chosen from H, Ci_i2 alkyl, C2_i2 alkenyl, C2-i 2 alkynyl, C1-12 haloalkyl, C2-i2 haloalkenyl, C2-j2 haloalkynyl, C6-i 8 aryl, and Cj.o heteroaryl groups, wherein Y1 and Y2 may join together along with the nitrogen atom to which they are attached to form a ring;

each R3, which may be identical or different, is independently chosen from

wherein each R , which may be identical or different, is independently chosen from H, Ci-i2 alkyl and CM2 haloalkyl groups, and wherein each R7, which may be identical or different, is independently chosen from Ci_8 alkyl, C2.8 alkenyl, C2-8 alkynyl, -OY3, -NHOH, -NHOCH3, -NHCN, and -NY3Y4 groups, wherein each Y3 and each Y4, which may be identical or different, are independently chosen from H, Ci_8 alkyl, C2_8 alkenyl, C2-8 alkynyl, Ci_8 haloalkyl, C2-8 haloalkenyl, and C2_8 haloalkynyl groups, wherein Y3 and Y4 may join together along with the nitrogen atom to which they are attached to form a ring;

each R4, which may be identical or different, is independently chosen from -CN, C1.4 alkyl, and C haloalkyl groups;

m is chosen from integers ranging from 2 to 256; and

L is chosen from linker groups, wherein the linker group is a dendrimer;

with the proviso that when m is 4, each R1 and each R4 is methyl, each R2 is

then the linker groups are not chosen from

2. The at least one compound according to claim 1 , with the proviso that when each R1 and each R4 is methyl, each R2 is -OC(=0)Ph, and each R3 is

then the linker groups are not chosen from

wherein p is chosen from integers ranging from 0 to 250.

3. At least one compound chosen from glycomimetic E-selectin antagonists of Formula (I):

prodrugs of Formula (I), and pharmaceutically acceptable salts of any of the foregoing, wherein

each R1, which may be identical or different, is independently chosen from H, Ci_i2 alkyl , C2-i2 alkenyl, C2-12 alkynyl, and -NHC(=0)R5 groups, wherein each R5, which may be identical or different, is independently chosen from Cj-12 alkyl, C2-i2 alkenyl, C2-i 2 alkynyl, C6- i 8 aryl, and Ci-n heteroaryl groups; each R2, which may be identical or different, is independently chosen from halo, - OY1 , -NY1 Y2, groups, wherein each Y1 and each Y2, which may be identical or different, are independently chosen from H, C n alkyl, C2-i2 alkenyl, C2-12 alkynyl, Ci-i2 haloalkyl, C2-12 haloalkenyl, C2.i2 haloalkynyl, C6-i 8 aryl, and C . heteroaryl groups, wherein Y1 and Y2 may join together along with the nitrogen atom to which they are attached to form a ring;

each R3, which may be identical or different, is independently chosen from

, an wherein each R6, which may be identical or different, is independently chosen from H, CM2 alkyl and Q.12 haloalkyl groups, and wherein each R7, which may be identical or different, is independently chosen from C,.8 alkyl, C2.8 alkenyl, C2_8 alkynyl, -OY3, -NHOH, -NHOCH3, -NHCN, and -NY3Y4 groups, wherein each Y3 and each Y4, which may be identical or different, are independently chosen from H, Q.s alkyl, C2-8 alkenyl, C2-8 alkynyl, Ci-8 haloalkyl, C2-8 haloalkenyl, and C2-8 haloalkynyl groups, wherein Y3 and Y4 may join together along with the nitrogen atom to which they are attached to form a ring;

each R4, which may be identical or different, is independently chosen from -CN, CM alkyl, and CM haloalkyl groups;

m is 2; and

L is chosen from

wherein Q is a chosen from

wherein R is chosen from H, Ci-8 alkyl, C6-i 8 aryl, C7.1 arylalkyl, and Ci-n heteroaryl ;roups and each p, which may be identical or different, is independently chosen from integers ranj ging from 0 to 250.

4. The at least one compound according to claim 3, wherein R is H.

g

5. The at least one compound according to claim 3, wherein R is benzyl.

6. The at least one compound according to any one of claims 3-5, wherein p is chosen from integers ranging from is 0 to 30.

7. The at least one compound according to claim 6, wherein p is 5.

8. The at least one compound according to claim 6, wherein p is 4.

9. The at least one compound according to claim 6, wherein p is 3.

10. The at least one compound according to claim 6, wherein p is 2.

1 1. The at least one compound according to claim 6, wherein p is 1.

12. The at least one compound according to claim 6, wherein p is 0

13. The at least one compound according to any one of claims 1 -12, wherein at least one

R1 is H.

14. The at least one compound according to any one of claims 1- 12, wherein at least one

R1 is methyl.

15. The at least one compound according to any one of claims 1-12, wherein at least one R1 is ethyl.

16. The at least one compound according to any one of claims 1-12, wherein at least one R1 is chosen from -NHC(=0)R5 groups.

17. The at least one compound according to claim 16, wherein at least one R5 is chosen from

groups, wherein each Z is independently chosen from H, -OH, CI, F, N3,™NH2, Q.8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C6-i4 aryl, -OCi_8 alkyl, -OC2-8 alkenyl, -OC2.8 alkynyl, and -OC6-14 aryl groups, wherein v is chosen from integers ranging from 0 to 3.

18. The at least one compound according to any preceding claim, wherein at least one R2 is H.

19. The at least one compound according to any one of claims 1-17, wherein at least one R2 is F.

20. The at least one compound according to any one of claims 1 -17, wherein at least one R2 is CI.

21. The at least one compound according to any one of claims 1-17, wherein at least one R2 is chosen from -OY1.

22. The at least one compound according to any one of claims 1 -17, wherein at least one R2 is chosen from -OC(=0)Y' .

23. The at least one compound according to any one of claims 1-17, wherein at least one R2 is chosen from -NY!Y2.

24. The at least one compound according to any one of claims 1-17, wherein at least one R2 is chosen from -NH(C=0)Y\

25. The at least one compound according to any one of claims 1-17, wherein at least one R2 is chosen from -NH(C=0)NY' Y2.

26. The at least one compound according to claim 21, claim 23, or claim 25, wherein at least one of Y1 and Y2 is H.

27. The at least one compound according to claim 21 , claim 23, or claim 25, wherein each of Y1 and Y2 is H.

28. The at least one compound according to any one of claims 21-26, wherein

Y 1 is methyl.

29. The at least one compound according to any one of claims 21-26, wherein

Υ' is phenyl. The at least one compound according to any one of claims 1-17, wherein at least one

R is chosen from

The at least one compound according to any preceding claim, wherein at least chosen from

32. The at least one compound according to any one of claims 1 -31, wherein at least one

R is chosen from

The at least one compound according to any one of claims 1-31 , wherein at least one

R is chosen from

34. The at least one compound according to claim 33, wherein at least one R6 is chosen from

35. The at least one compound according to claim 33, wherein at least one R6 is chosen from

36. The at least one compound according to any preceding claim, wherein at least one R7 is -OH.

37. The at least one compound according to any one of claims 1-36, wherein at least one R7 is chosen from

38. The at least one compound according to claim 37, wherein at least one R7 is chosen from

39. The at least one compound according to any preceding claim, wherein at least one R is CH3

40. The at least one compound according to any one of claims 1-38, wherein at least one R4 is chosen from CH2F, CHF2, and CF3.

41. The at least one compound according to any one of claims 1-40, wherein at least one R4 is CF3.

42. The at least one compound according to any one of claims 1-3, wherein the compound is chosen from compounds having the following Formula:

The at least one compound according to any one of claims 1-3, wherein the compound chosen from compounds having the following Formula:

44. The at least one compound according to any one of claims 1-3, wherein the compound is chosen from compounds having the following Formula:

45. The at least one compound according to claims 1-3, wherein the compound is chosen from compounds having the following Formula:

46. The at least one compound according to claim 1 or claim 2, wherein m is 4.

47. The at least one compound according to claim 1 or claim 2, wherein m is 3.

48. The at least one compound according to any preceding claim, wherein the compound is symmetrical.

49. A composition comprising at least one compound according to any preceding claim and at least one additional pharmaceutically acceptable ingredient.

50. A method for treatment and/or prevention of at least one disease, disorder, and/or condition where inhibition of E-selectin mediated functions is useful, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1 -48.

51. A method for treatment and/or prevention of at least one inflammatory disease, disorder, and/or condition, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-48.

52. A method for treatment and/or prevention of metastasis of cancer cells, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-48.

53. A method for inhibiting infiltration of cancer cells into bone marrow, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-48.

54. A method for inhibiting adhesion of a tumor cell that expresses a ligand of E-selectin to an endothelial cell expressing E-selectin, the method comprising contacting the endothelial cell with an effective amount of at least one compound of any one of claims 1-48.

55. The method according to claim 54, wherein the endothelial cell is present in bone marrow.

56. A method for treatment and/or prevention of thrombosis, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-48.

57. A method for treatment and/or prevention of cancer, the method comprising administering to a subject in need thereof (a) an effective amount of at least one compound of any one of claims 1-48 and (b) at least one of therapy chosen from (i) chemotherapy and (ii) radiotherapy.

58. A method for enhancing hematopoietic stem cell survival, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1 -48.

59. The method according to claim 58, wherein the subject has cancer and has received or will receive chemotherapy and/or radiotherapy.

60. A method for treatment and/or prevention of mucositis, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-48.

61. The method according to claim 60, wherein the mucositis is oral mucositis, esophageal mucositis, and/or gastrointestinal mucositis.

62. The method according to claim 60, wherein the subject is afflicted with head and neck, breast, lung, ovarian, prostate, lymphatic, leukemic, and/or gastrointestinal cancer.

63. A method for mobilizing cells from the bone marrow, the method comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-48.

64. The method according to claim 63, wherein the cells are hematopoietic cells and/or tumor cells.

Description:
Highly Potent Mtiltimeric. E-Setectln Antagonists fOOOl] This- application claims the ' benefit under 35 IJ.S.C. § i .19(e) to U.S. Frovisiotial Application Nos. 62/405,792 filed October 7, 2016 and 62/451 ,415 filed January 27, 2017, which applications are -incorporated, by .reference herein in their entire^

10002} Compounds, .compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition associated wi th E-selec-tm activity including, for example, inflammatory diseases and cancers, are disclosed herein.

(0603) When -a tissue is infected or damaged, the -inflammatory process directs leukocytes and other immune system components to the site of infection or injury. Within this process, leukocytes play an important role in the engu!fment and digestion of microorganisms. The recrwi raent of leukocytes to infected- or : damaged tissue is critical for ' mounting an effective immune defense,

[0004] ' Seiectins are a group of structurally similar cel l surface receptors important ' For mediating leukocyte binding to endothelial cells. These proteins are type 1 membrane proteins and are composed o f an amino terminal lectin domain, an epidermal growth fac tor ( ' EGF)-like domain, a variable number of complement receptor related repeats, a hydrophobic domain spanning region and a cytoplasmic domain. The binding interactions appear to be mediated by contact of the lectio domain of the seiectins and various carbohydrate ligands.

[0005] There are three known seiectins: E-selectin, P-seJectin, and L-selectin. E-selectra is found on the surface of activated endothelial cells, which line the interior wall of capillaries. E-selectin hinds to the carbohydrate sialyl-Lewis* (sLe ), which is presented as a

glycoprotein or gtycolipid on the surface of certain leukocytes (monocytes and neutrophils) and helps these cells adhere to capillary walls in areas where .surrounding tissue is miected or damaged; and E-selectih also binds to sialyl-Le is 5 (sLe s ), which is expressed on many tumor cells. P-seiectin is expressed on inflamed endothelium and platelets, and also recognizes sLe s and sLe s , but also contains a second site that interacts with sulfated tyrosine. The expression of E-selectin and P-selectin is generally increased when the tissue adjacent to a capillary is infected or damaged. L-selectin is expressed on leukocytes. Selectin-mediated intercellular adhesion is an example of a selectin-mediated function. |ίΜΜί6] Although selectm-me iaied ceil adhesion is required for fighting infection and destroying foreign material, there are situations in which such cell adhesion is undesirable or excessive, resulting in tissue damage instead of repair. For example, many pathologies (such as autoimmune and mftammatory diseases, shock and reperfusion injuries) involve abnormal adhesion of white blood cells. Such abnormal cell adhesion may also lay a role in transplant and graft rejection. In addition, some circulating cancer ceils appear to take advantage of the inflammatory mechanism to bind to activated endothelium, in such circumstances,

modulation of selectm-mediaied intercellular adhesio may be desirable fO f Modulators of seieciin-mediated function include the PSGL-1 protein (and smalle peptide fragments), f hcbidan, glyc rr!rizin (and derivatives), sulfated lactose derivatives, heparin and hepari -fragments, sulfated hyaluronic acid, condroitin sulfate, sulfated dextran, sulfatides, and particular glycornimetic compounds (see, e.g., US E44J78). To date, all but the glycomimetics have shown to be unsuitable for drug development due to insufficient activity, toxicity, tack of specificity, poor ADME characteristics, and/or availability of material.

|θθί>8{ Accordingly, there is a need in the art for identifying inhibitors of selectut- mediated function, e.g., of selectin-dependent cell adhesion, and for the development of methods employing such compounds. The present disclosure may fulfill one or more of these needs and/or may provide other advantages.

|ΘΘΘ9{ Compounds, compositions, and methods for treating and/or preventing (i.e.., reducing the likelihood of occurrence or reoccorance) at least one disease, disorder , and/or condition, in. which inhibiting binding of E-seleeii to one or more H-selectm Hgauds may play a role are disclosed. QOI j Disclosed are highly potent multitueric E-selecti antagonists of Formula (I):

(I)

prodrugs of Formula (I), and pharmaceutically acceptable salts of an of the foregoing, wherein each R 1 , R 2 , R'\ and 4 are defined herein.

{00 i I j As used herein, 'compound of Formula 0)' includes muhimeric E-seiectm antagonists of Formula (I), phammceMticauy acceptable salts of mukjmenic E-selectin antagonists of Formula (1),■ prodrugs of multimerie E~selectin antagonists of Formula (I), and pharmaceulicalSy acceptable -salts of prodrugs of muhimeric E-selectin antagonists of

Formula (1).

[0012] lo some embodiments, harmace tical compositions comprising- at least one compound of Formula (I) and optionally at least one additional pharmaceutically acceptable ingredient are presented,

|0013j in some embodiments, a method for treatment and/or prevention of at least one disease, disorder, and/or condition where imbibition, of E-sei.eetin .mediated function is useful is disclosed, the method comprising administering to a subject in need thereof an. effective amount of at least one compound of Formula (I) or a pharmaceutical composition comprising at least one compound of Formula (I).

[0014] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the disclosed embodiments may be practiced without these details. In other instances, welt-known structures have not been shown, or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. These and other embodiments will become apparent upon reference to the following detailed description and attached drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

|WI5j Figure 1 is a diagram illustratin -the synthesis of intermediate 2.

[0016} Figure 2 is a diagram illustrating the synthesis of intermediate 7.

{0017] Figure 3 is a diagram illustrating the synthesis of intermedi ate 9.

[0018] Figure 4 is a diagram illustrating the synthesis of compound 1 1.

[Θ0Ι 9] Figure 5 is a diagram illustrating the synthesis of compound 20.

|902ij Figure 6 is a diagra illustrating the synthesis of compound 27.

[ΘΘ2Ι j Figure 7 is a diagram illustrating the synthesis of compound 29.

|0022{ Figure 8 is a diagram illustrating the synthesis of compound 31.

[0023! Figure 9A is a diagram illustrating the synthesis of compound 32.

[Θ024} Figure 9B is a diagram illustrating a altnerarive synthesis of compound 32.

{0025} Figure 10 is a diagram illustrating the synthesis of compound 35.

|ΘΘ26] Figure I I is a diagram illustrating the synthesis of compound 38. f oei? } Figure 12 is a diagram- illustrating the synthesis -Of compound 42,

[0028! Figure 13 is a diagram illustrating the synthesis of compound 44.

[0 29 ' j Figure 14 is a diagram illustrating the synthesis of compound 45.

[0030] Disclosed herein are highly potent mullimeric E-seleetin antagonists,

pharmaceutical compositions comprisin the same, and methods for inhibiting E-selectin- mediated functions using the same. The compounds and compositions of the present disclosure may be useful for treating and/or preventing at least one disease, disorder, and/or condition that is treatable by inhibiting binding of E-selectin to one or more E-selectin ligands.

[0031 J The compounds of the present disclosure ha e been found to be highly potent raulti eric E-selectin antagonists, the potency being many times greater than the monomer. The compounds of the present disclosure may also have at least one improved

physicocheniieai pharmacological, and/or pharmacokinetic property.

[0032 j In some embodiments, presented are highly potent multimeric E-selecti antagonists of Formula (I):

(1) prodrugs- of Formula (I), and pharmaceutically acceptable salts of any of the foregoing,. wherein

each R s , which may be identical or different i independently chosen from H s Gi.ts alkyl , C¾.K alkenyl, a-ta a!kynyi, and --H!iCf- J ' groups, wherein each " , which -may be identical or different, is independently chosen from C ? alky!., C2-12 aikerryi, Ci-n aikytvyl Ct is aryl, and C1-0 heteroaryl groups;

each R"% which may be identical or different, is independently chosen from halo,—

OY\

~m l Y 2 > ~O ( O) , ~NHC(= 0)Y\ and ^HC(-0) Y½ s mups, wherein each Y 1 and each Y t( , which may be identical or different, are independently chosen frornH, CM2 alkyl,. CM2 alkenyl, Ο η alkynyl, Ci-n haioalkyl ^n haloalkenyi C^n haSoalkynyi, C i¾ aryl. and CM S heteroaryl groups, wherein Y ' and Y " may join together along with the nitrogen atom to which they are attached to form a ring;

each R\ which may be identical or different, is independently chosen from

and wherein each R whic may be identical or different, is independently chosen from H } Cj.n alkyl and CM S haloalkyl groups, and wherein each R'„ which may be identical or different, is independently chosen from Q,s alkyl, alkenyl, Cj.s alkynyl, -OY\ -ΝΗΌΗ, -NHOCH3, -NHCN, and -ΝΥ ' Ύ groups, wherein each Y 3 and eac Y ' which may be identical or different, are independently chosen from H, O-s alkyl, C : -s aikenyl, C^-s alkynyl, Ci-» haloalkyl C -s hatoalkeoyi and C?-s haloa!kynyl groups, wherein Y ' and Y 4 may join together along with the nitrogen atom to which they are attached to form a ring;

each R 4 , which may be identical or different,, is independently chose from. -CN, CM alkyl, and CM haloalkyl groups;

in is chosen from integers ranging from 2 to 256; and

L is chosen from linker groups;

with the proviso that when ra. is 4, each. R l and each R 4 is methyl, each. R * is

~0C(=O)Ph, and each R 3' is

then the linker groups are not chosen from

|ΘΘ33| In some embodiments, at least one compound is chosen from compounds of Formula (Γ):

(I) prodrugs of Formula (I), and p araaceatically acceptable sails of any of the fore-going, wherein

each R. { , which may be identical or different, is independently chosen from H, Cj.j* alkyl , C^n alkenyl, C 2 -u alkynyl, and -NHC(~0)R 5 groups, wherein each R 5 , which may be identical or different, is independently chosen from C ? ..r? alkyl, aikenyi i-n. alkyuyl., C«. aryl, and CM* hetefoaryl groups; each R 2 , which may be identical or different, is independently chosen from halo, -

OY } ,

·~ΝΥ Υ 2 , X:«m A , "NHC(=0)Y s , and™NHC( 3)NY ' Y 3 groups, wherein each Y 1 and each Y\ which may be identical or different, are independently chosen from H, C alkyl, C;;-i2 aikenyl, Ci-n alkynyl. C M haloalkyl, >-n haioalkenyl, Cs-n aloalkynyl, C G -U aryl, and Ci-13 heteroaryl groups, wherein Y ! and Y" raay join together along with the nitrogen atom to which they are attached to form a ring;

each R ' , which ma be identical or different, is independently chosen from

wherein each R", which may lie identical or different, is independently chosen from H, C|.s alkyl and CMS haloalkyl groups, and wherein each R ' , which may he identical or different, is independently chosen ff i Ct-g alkyl, aikenyl, C2-8 alkynyl, -ΟΥ , -NHOH, -NHOCH 3 , -NHCN, and -NY J Y * groups, wherein each Y '! and each Y*, which may be identical or different, are independently chosen fiomH, Cua alkyl. C' -g aikenyl, Qj-g alkynyl, Cj-g haloalkyl, C?.s haioalkenyl, and C?-s haloalkynyl groups, wherein Y J and Y 4 may join together along with, the nitrogen atom, to which they are .attached to form a ring;

each R 4 , which may be identical or different, is independently chosen from -CN, CM alkyl, and C M haloalkyl groups;

m is chosen from, integers ranging from 2 to 256; and

L is chosen from linker groups;

with the proviso that when m is 4, each R ! and each R 4 is methyl, each R" is

OC( ::: 0)Ph and each R' is

then the ί taker grou s are not chosen from

wherein p is chosen froni integers ranging from 0 to 250.

[0034] In some embodimenis, at ieasi one R ! is H, In some embodimenis, ai ieasi one R J is chosen irom CVr alkyl groups, in some embodiments, at least one 1 is chosen irom C 5 .<; alky! groups. In some embodiments, ai least one R 1 is methyl In some embodiments, at least one R l is ethyl.

[0035] I some embodimenis, each R l is H, in some embodiments, each R ! , which may be identical or different, is independently chosen from Cj-n alky! groups. In some embodiments, each R ! , which may be identical or different, is independently chosen from Q. 6 alkyi groups, in some- embodiments, each R 5 is identical and chosen from C alkyl groups. Irs some embodiments, each R 1 is methyl. in some embodiments, each R } is ethyl.

[0036j In some embodiments, at ieasi one R f is chosen from ~NHC(=0)R :> groups. In some embodiments, each R f is chosen from ~NHC(=0)R > groups. In some embodime ts, at. least one R 5 is chosen from H, C;.s alkyl, C is aryl, and CM ? heteroaryl groups. In some embodiments, each R s is chosen from H, Ci-s alkyl, C is aryi, and MS heteroaryl groups, In some embodiments, at least one R s is chosen from

groups, wherein each Z is independently chosen from E, -OH, Cf, F. , -Nl¾, alkyk C2-8.aiken.yl., C-^ alkynyl, C^ axy , -G€;.¾ aikyJ, -OC?.*, aJkenyl, ~OC%.s alkyny.1, and -OC$.j aryl groups, wherein v is chosen from integers ranging from 0 to 3.

(0037] In some embodiments, at least one R 2 is chosen from halo groups. In some embodiments, at least one is .fluoro. In some embodiments, at least one R J is chloro. In some embodiments, at least one is chosen from OY : groups, in some embodiments, at least one 2 is -OH. In some embodiments, at least one E * is chosen torn -NY 1 Y 2 groups. In some embodiments, at ieast one R 2 is chosen from -0€(=0}Υ ! groups * In some embodiments, at ieasi one R '; is chosen ftom -NHC( s O)Y } groups. In some embodiments, at least one R 2 is chosen from - HC( != 0) Y i Y^ groups.

[0038] In some embodiments, each R\ which may be identical or different, is

independently chosen ftom halo groups. Jn some embodiments, each ' is fluoro. In some embodiments, each R 3 is chloro. In some embodiments, each R\ which may be identical or different, is independently chosen from -QY 1 groups. In some embodiments, each R ' is -OH. In some embodiments, each R~, which may be ideniicai or different, is independently chosen from

™ΝΥΎ : groups. In some embodiments, each R', which may be identical or different, is independently chosen from -OC( ::: 0)Y ! groups. In some embodiments, each R ~ ., which may be identical or different, is independently chosen from --NHC(-- : 0)Y' groups. In some embodiments, each R " , which may be identical or different, is independently chosen from ~ NHCi~Q)NY I Y i groups. In some embodiments, each ' is identical and chosen from ~OY ! groups. In some embodiments, each " R is identical and chose from -NY 1 ? 1' groups. In some . .embodiments, each 2 is identical and chosen from ~OCi Q)Y ! groups, in some embodiments, each is identical I ' some

embodiments, each " is identical and chosen ftom - HC(=0)N ! Y * groups.

[0039] In some embodiments, at least one Y* and/or at Ieast one Y' ~ is chosen from H, Cj. n alkyl, C *» aryl, and C $ .13 heteroaryl groups. In some embodiments, at least one Y 1 and/or at least one Y " is H, In some embodiments, at least one Y ! and or at least one Y 2 is chosen from C .n aikyl groups. In some embodiments, at least one Y 1 and or at least one Y 2 is chosen from CVs aikyl groups, in some embodiments, at least one Y ! and/or at least, one Y l is chosen from CM aikyl groups. In some embodiments, at least one Y ! and/or at least one

- I I - Ύ ι is chosen, from C is aryl groups. In some embodiments, at least m Y i and or at least one Y " is chosen from C¾.^ aryl groups, to some embodiments, at least one Y' and/or at least one is chosen from C io aryl groups. In some embodiments, at least one * aad/or at least one Y 2 is chosen from heteroaryl groups. In some embodiments, at least one Y* and/or at least one Y' ; is chosen from Cs-s heteroaryl groups. In some embodiments, at least one Y 1 and/or at least one Y 2 is chosen from Cj.s heteroaryl groups. In some embodiments, at least one Y ! and/or at least one Y 2 is chosen from CJ.J heteroaryl groups.

(0040j In some embodiments, each Y s , which may be identical or different is

independently chosen from H, C alk i C is aryl, and C^ heteroaryl groups. In som embodiments, each Y l is H. In some. embodiments^ each Y 1 , which may he identical or different, is independently chosen from CMS s!ky! groups, in some embodiments, each. Y 1 , which may he identical or different, is independently chosen from Ci.s alkyl groups, in some embodiments, each Y 5 , which may be identical or different, is independently chosen from Cj. 4 alkyl groups. In some embodiments, each Y \ which may be identical or different, is independently chosen from C JS aryl groups, in some embodiments, each Y', which may be identical or different, is independently chosen from C aryl groups. In some embodiments, each Y ' which may be identical or different, is independently chosen from Cg-jo aryl groups. In some embodiments, each Y j , which may be identical or d fferent, is independently chosen from C K; heteroaryl groups. In some embodiments, each Y 1 , which may be identical or different, is independently chosen from C t .y heteroar l groups. In some embodiments, each Y ! , which may be identical or different, is independently chosen from Ct..¾ heteroaryl groups. In some embodiments, each Y* s which may be identical or different, is independently chosen from C t heteroaryl groups,

[0Θ4Ϊ] In some embodiments,, each Y 3 , which may be identical or different, is independently chosen from H, O-12 alkyl. Cw* aryl, and CMS heteroaryl groups. In some embodiments, each Y a is fl In some embodiments, each Y 3 , which may be identical or different, is independently chosen from Cj-u alkyl groups. In some embodiments, each \ which may be identical or different, is independently chosen from C;.¾ alkyl groups. In some embodiments, each Y ~ , which may be identical or different, is independently chosen from Cj. 4 alkyl groups, hi some embodiments, each Y 2 , which may be identical or different, is independently chosen from Ce-ts aryl groups. In some embodiments, each Y\ which may be identical or different, is independently chosen from Q,.u aryi groups. In some embodiments, each Y\ which may be identical or different, is independently chosen from C^o aryi groups.

In some embodiments, each Y ' \ which may be identical or different, is independently chosen from C 3 heteroaryi groups. In some embodiments, each Y', which may be identical or different, is independently chosen from€·.< > heteroaryi groups. In some embodiments, each Y 2 , which may be identical or different, is independently chosen from Ct..¾ heteroary i groups. In some embodiments, each Y 3 , which may be identical or different, is independently chosen from Ci-3 heteroaryi groups .

[0042] In some embodiments, each Y' is identical and chosen from H, C rs alkyi, Qs-nt aryi, and C \ . $ heteroaryi groups. In some embodiments, each Y ! is identical and chosen from Cw 2 alkyi groups. In some embodiments, each Y * is identical and chosen from C S alkyi groups, in some embodiments, each Y 1 is identical and chosen from C alkyi groups, in some embodiments, each Y 1 is identical and chosen from C(.-vi aryi groups. In some embodiments, each Y i is identical and chosen from C¾.n aryi groups. In some embodiments, each Y 5 is identical and chosen from Cg-jo aryi groups, in some embodiments, each Y ! is identical and chosen from€μ > heteroaryi groups. In some embodiments, each Y 3 ts identical and chosen from C 1 -9 heteroaryi groups. In some embodiments, each Y 1 is identical and chosen from C5.5 heteroaryi groups. In some embodiments, each Y 1 is identical and chosen from C' 5 heteroaryi groups.

[ΘΘ43] In some embodiments, each Y J is identical and chosen from H, ^n alkyi, C< J§ aryi, and C 3 heteroaryi groups. In some embodiments, each Y" is identical and chosen ftoraCi- 1 2 alkyi groups, i some embodimenis, each Y * is identical and chosen from Cj.s alkyi groups, in some embodiments, each Y" : is identical and chosen, from C 1 .4 alkyi groups. In some embodiments, each Y 2 is identical and chosen from S-JS aryi groups. In som embodiments, each Y 5 is identical and chosen from C t s:; aryi groups. In some embodiments, each Y " is identical and chosen from C io aryi groaps. In some embodiments, each Y" is identical and chosen from C S heteroaryi groups. In some embodiments, each Y :: is identical and chosen from C5.9 heteroaryi groups. In some embodiments, each Y is identical and chosen from C».s heteroaryi groups. In some embodiments, each Y * is identical and chosen from Cj„3 heteroaryi groups. [0644] In some embodiments * at least one Y l is methyl, in some embodiments, a least one Y ! is phenyl, io some embodiments, each Y' is methyl. In some embodiments, each Y 1 is phenyl in some embodiments, at least one Y 1 is methyl and at least one Y 5 is H, in some embodiments, at least one Y s is phenyl and at least one Y J is H. in some embodiments, each Y ! is methyl and each Y 3 is H. in some embodiments, each Y ! is phenyl and each Y 2 is H.

(ΘΘ45) In some embodiments, at least one R : is chosen from

[0Θ46] In some embodiments, each R : is

(ΘΘ47) in some embodiments, each R~ is

[0048] In some embodiments, each R " is

[ΘΘ49] In some embodiments, at least one R > , which may be identical or different, is independently chosen from l&OS I In some embodiments * at least one R J , which may be identical or different, is independently chosen from

I&051I Io some embodiments, at least one R\ which may be identical or different, is independently chosen from

[ΘΘ52] In some embodiments, at least one R" *

[0053] in some embodiments,, each R*, which may be identical or eat. is independently chosen from

(.0054] in some embodiments, each ft 3 , which may be identical or different, is independentl chosen from

|0Θ55| In some em odiments, each R:\ which may he identical or different, is

independently chosen from

lo some embodiments, each R

|0Θ57| In some embodiments, each R ' is identical and chosen from

[Θ058] In some embodiments, each R ! is identical and chosen from

10059! In some embodiments, each R 3 is identical and chosen from

(0069) In some embodiments, each R which may be identical or difierent, is

independently chosen from Ci-n alkyl and haioaikyl groups, in some embodiments, each R ft , which may he identical or different, is independently chosen from CM2 alkyl groups. in some embodi ts, each R 6 , which may be identical or different, is independently chosen from C' H alkyl groups. In some embodiments, each R\ which may be identical or different, is independently chosen from C alkyl groups, in some embodiments, each R F> , which may be identical or different, is independently chosen from CM alkyl groups. In some embodiments, each R", which may be identical or different, is independently chosen from C 2 - - alkyl groups. In some embodiments, each R H , which ma be identical or different, is independently chosen from C ? haloaikyl groups. In some embodiments, each R*, which may be identical or different, is independently chosen from haloaikyl groups. In some embodiments, each R 6 , which may be identical or different, is independently chosen from Cj. 5 haloaikyl groups.

1 . 0061] In some embodiments, each R ft is identical and chosen from C» 2 alkyl haloaikyl groups, in some embodiments, each R* is identical and chosen from C J .J J alkyl groups. In some embodiments, each R° is identical and chosen from alkyl groups. In some embodiments, each is identical and chosen, from Cj.j alkyl groups. In some embodiments, each R 6 is identical and chosen from C2-4 alkyl groups, in some embodiments, each R 6 is identical and chosen from C2-7 alkyl groups. In some embodiments, each " is identical and chosen from C J> haloaikyl groups. In some embodiments, each R 6 is identical and chosen from Cj-g haloaikyl groups. In some embodiments, each R 6 is identical and chosen from C$.j haloalkyi groups.

[ΘΘ62] In some embodiments, at least one R° is chose from

- 18-

ΑΘί»8] In some embodiments, at least one W is -QH. In some embo iments, at least one R is chosen from -NO Y ' ' groups. In some embodiments, at least one R' is chosen .from - NY J Y 4 groups. In some embodiments, each R ' , which may be identical or different, s independently chosen from ~NHY J groups. In some embodiments, each R', which may be identical or difFereni, is independently chosen from -ΝΥΎ* groups. In some embodiments, each is identical and chosen from -NHY"' groups, in some embodiments, each R' is identical and chosen from

-N ' Y'Y 4 groups. In some embodiments, each R' is -OH. [0669] In some embodiments * at least one Y J and/or- t least one Y 4 is chosen from Ci-s alkyl and C s haloalkyl groups. In some embodiments, at least one Y and/or at least one Y 4 is chosen from Cm alky! groups. In some embodiments, at least one Y J and/or at least one Y is chosen from C t haloalkyl groups, in some embodiments, each Υ and or each Y 4 , which may be identical or different, are independently chosen from Cf-s alkyl and C -s haloalkyl groups, in some embodiments, each Y ' ' and/or each Y\ which may be identical or different, are independently chosen from C alkyl groups. In some embodiments, each Y ! and/or each Y , which may be identical or different, are independently chosen from C a haloalkyl groups.

1ΘΘ70} In some embodiments, each Y 3 is identical and chosen front Cs-a alkyl and haloalkyl groups. In some embodiments, each Y ~ is identical and chosen front C t -s alkyl groups. In some embodiments, each Y 1 is identical and chosen from haloalkyl groups.

[0071] In some embodiments, each Y 4 is identical and chosen from Ci-s alkyl and Cj.& haloalkyl groups, in some embodiments, each Y * is identical and chosen from C & alkyl groups. In some embodiments, each Y 4 is identical and chosen from Cj-s haloalkyl groups,

(ΘΘ72) In some embodiments, at least one Y 3 and/or at least one Y 4 is methyl. In some embodiments, at least one Y " and/or at least one Y " is ethyl, in some embodiments, at least one Υ and/or at least one Y 4 is II. in some embodiments, each Y ' ' and/or each Y 4 is methyl. In some embodiments, each Y* and/or each Y 4 is ethyl. In some embodiments, each Y 5 and/or each Y 4 is H.

[0075] In some embodiments, at least one Y <: and at least one Y 5 join together along with the nitrogen, atom to which they are attached to form a ring. In some embodiments,, each Y* and each Y J join together along with the nitrogen atom to which they are attached to form a ring.

[0074] In some embodiments, at least one R' is chosen from

f 8075} In som embodiments, each R ' is

(0076) lo some embodiments, each R' is

| 077] in some embodiments, each R' is

[0078] Irs some embodiments, each R is

(0079} tn som embodiment, each R ' is

[ΘΘ80] lo some embodiments, at least one R 4 is chosen from halomethyl groups, in some embodiments, at least one R 4 is C ?. In some embodiments, at least one R 4 is CH.¾. In some embodiments, at least one R 4 is CN. in some embodiments, each R 4 , which may be identical or -different, is independentl -chosen from aloraethyt groups. In some embodiments, each R l is identieai and chosen from halomethyl grou s. In some embodiments, each .R 4 is CF;¾. In some embodiments, each R 4 is t¾. in some embodiments, each R 4 is CN.

|M8l] In some embodiments, m is chosen from integers ranging from 2 to 1.28, In some embodiments, m is chosen from integers ranging from 2 to 64. In some embodiments, is chosen from integers ranging from 2 to 32. In some embodiments, m is chosen from integers ranging from 2 to 16. In some embodiments, m is chosen from integers ranging from 2 to 8. hi some embodiments, m is chosen from integers ranging from 2 to 4. In some embodiments, m is 4. in some embodiments, m is 3, in some embodiments, m is 2. j 82j In some embodiments, linker groups may be chosen from groups comprising spacer groups, such spacer groups as, for example, -(CHj) 5 - and -0(CH 3 ) p -, wherein p is chosen from integers ranging from 1 to 250. Other non-limiting examples of spacer groups ittemde carbonyi groups and earbotryi-eomakving groups such as, for example, -amide groups. A non-limiting example of a spacer group is

H O

O f0083j In some embodiments, the linker group is chosen from

-23 -

|0084J Other linker groups, such as, for example, polyethylene glycols (PEGs) and -C(=0)~.NH CH?} p -C(=0)~ H-, wherein p is chosen from integers ranging from 1 to 250, will he familiar to those of ordinary skill in the art and/or those in possession of the present disclosure-.

( 85| In some embodiments, the linker group is

|0087}

-CI-fcNHCI¾-, and ™C{~0)NHCHr. la some embodiments, the linker group is

[OeSS] !n some eoibodiraeftis, L Is chosen from dendnraers, in seme embodimeais, L is chosen from polyamidoamine ("PAMAM") dendnmers. In some -embodiments-, L is chosen from PAMAM dei iriraers comprisin ' s cGinamic. In some embodiments, L is PAMAM GO generating a tetramer. In some embodiments, L is PAM AM Gi generating an ociamer, in some embodiments, L is PAMAM G2 generating a 16-raer, in some embodiments,. L is PAMAM G3 generating a 32-mer. In some embodiments, L is PAMAM G4 generating a 64- mer. In some embodiments, L is PAMAM 05 generating a 128-mer.

[00891 In some embodiments. L is chosen from

wherein Q is a chosen from

wherein R 8 is chosen from H, Cj-s lkyi, Ce-is aryl, C?.}9 arylaiky.l, and CMS heteroaryl groups and each p, which may be identical or different, is independently chosen, from integers ranging from 0 to 250. In some embodiments, R ¾ is chosen from C;.¾ aJkyi. In some embodiments, R is chosen from C7- 1 9 arylalkyl. In some embodiments, * is H. In some embodiments, R 8 is benzyl.

In some embodiments, I, is chosen from

wherein p i chosen from integers ranging from. 0 to 250. (ΘΘ91 J in some embodiments, L is chosen from

Ι&092Ί In some embodimenis, L is chosen from

wherein p is chosen from integers ranging from 0 to 250. f 6093 J Is. some embodiments, L is chosen firom

wherein p is chosen from integers ranging from 0 to 250.

[0094] In some embodimenis, L is chosen from

[0095] In some embodiments, I. is chosen from

wherein p is chosen from integers ranging from 0 to 250. f ΘΘ97] In some embodiments, L. i s choses irom

herei.ii p is chosen from integers rangin from 0 to 250,

ΙΘΘ 8] to some -embodiments, p is chosen from integers ranging from 0 to 200. In some embodiments, p is chosen from integers ranging from 0 to 150. In some embodiments, p is chosen from mtegers ranging from 0 to 100. In some embodiments, p is chosen from integers ranging from 0 to 50. In some embodiments, p is chosen from mtegers ranging from 0 to 30. In some embodiments, p is chosen from integers ranging from 0 to 15. Irs some embodiments, p is chosen from integers ranging from 0 to 10. in some embodiments., p is chosen from integers ranging from 0 to 5. In some embodiments, p is 1 17. m some embodiments, p is 25. In some embodiments, p is 21. In some embodimenis, p is J 7. in some embodiments p is 13. In some embodiments,, is 10. In some embodiments, p. is 8. In some embodiments, p is 6. In some embodimeiHs, p is 5, In some embodiments, p is 4. I» some embodiments, p is 3. in some embodiments,, p is 2, In some embodiments, p is ! . In some embodiments,, p is 0. f In some embodiments, at least one compound is chosen from compounds of

Formula (Ϊ), wherein said compound is symmetrical,

(θϋΐθυ j In some embodiments, at least one compound is chosen from compounds havin the following ' Formula:

J00101 ] In some embodiments, at least one compoand is chosen from compounds having the following Formula:

(001921 i» some embodiments, at least one compound is chosen irom compounds having the following Formula:

wherein is chosen from integers ranging from 0 to 250. in some embodiments, p is chosen from integers ranging from 0 to 200. In some embodiments, p is chosen, from in tegers ranging from 0 to 150. In some embodiments, p is chosen from integers rangin from 0 to 100. in some embodiments, p is ciiosen from integers ranging from 0 to 50. In some embodiments, p is chosen from integers ranging from 0 to 25. in some embodiments, p is chose from integers ranging from 0 to 13. In some embodiments, p is chosen from integers ranging from 0 to 10.

[0Θ 103] in some embodiments, at least one compound is chosen from compounds ha ving the following Formulae:

[00104] In some embodiments, ai least one compound is chosen from compounds ha ving the following Formula:

wherein is chosen from integers ranging from 0 to 250. in some embodiments, p is chosen from integers ranging from 0 to 200. In some embodiments, p is cliosen. from in tegers ranging from 0 to 150, In some embodiments, p is chosen from integers rangin from 0 to 100. in some embodiments, p is ciiosen from integers ranging irom 0 to 50. In some embodiments, p is chosen from integers ranging from 0 to 25. in some embodiments, p is chose from integers ranging from 0 to 13. In some embodiments, p is chosen from integers ranging from 0 to 10. hi some embodiments, p is chosen from integers ranging from 0 to 5. θθίβδ] in some embodiments, at least one compoitnd is chosen from compounds having the followin Formulae:

|ΘΘ166| In some embodiments, at least one comp und is chosen from compounds havin the following Formula: wherein R is chosen from R, C}.» a!kyl, Ce-jg aryt C?-I¾I Sry ky.1. and CM 5 heieroaryt groups and each p, which may be identical or different, is inde endently chosen from, integer ranging fro 0 to 250, In some embodiments, R* is chosen from H, Ci-s aHcyl, and C ? .i*> aiy kyl groups. In some embodiments, R ¾ is chosen from alkyl groups. In some embodiments, R* is chosen from C?.» arylalk l groups. In some embodiments, R 8 is H, In some embodiments, R h is benzyl. In some embodiments, each p is identical and chosen from integers ranging from 0 to 250. in some embodiments, p is chosen from integers ranging from 0 to 200. in some embodiments, p is chosen from integers ranging from 0 to 150, in some embodiments, p is chosen from integers ranging from 0 i 100. i n some embodiments, p is chosen from integers ranging from 0 to 50. In some embodimenls, p is chosen from integers ranging from 0 to 25. In some embodiments, p is chosen from integers ranging from 0 to 13. In some embodiments, p is ciiosen from integers ranging from 0 to 1 , In some embodiments, p is chosen from integers ranging from 0 to 5.

I&O 1 7] in some embodiments, at least one compound is chosen from compounds havin the following Formulae:

and

(00!08j In some embodiments, ai least one compoand is chosen irom compounds haying the fbliowiRa " Formula:

100109) In some embodiments, ai least one compoand is chosen from compounds having the following Forinaia:

wherein p is chosen from integers ranging from 0 to 250, in some embodiments,, p is chosen from integers ranging from 0 to 200. In some embodiments, p is chosen from integers ranging from 0 to 150, in some embodiments, p is chosen from integers ranging from 0 to 100. la some embodiments, p is chosen from integers ranging from 0 to 50, In some embodiments, p is chose from, integers ranging from 0 to .25. In some emb d e ts, p is chosen from integers rangirig from 0 to 1 . to some embodiments, p is chosen from integers ranging from.0 to 1

[ΘΘΙ 11 j In some embodiments, at least one compound is chosen from compounds having the following .Formulae:

and

[00112] Irs some embodiments, at least one compound is chose frorn compounds havmg the following .Formula:

wherein p is chosen from integers ranging from 0 to 250. In some, embodiments, p is chosen from integers ranging from 0 to 200. In some embodiments, p is chosen fro integers ranging from 0 to 150. in some emb dimems, p is chosen from integers ranging from 0 to 100. in some embodiments, p is chosen from integers ranging from 0 to 50. .to some embodiments, p is chosen from integers ranging from 0 to 25. In some embodiments, p is chosen from integers ranging from 0 to 13. in some embodiments, p is chosen from integers ranging from to i t ) .

[001.1.3] In some embodiments, at least one compound is chosen from compounds havin the following ormulae:

|00ii4] in some embodiments, at least one compound is chosen irom compounds haying the following Formula:

(06115 In -some embodiments, at least one compound is chosen from compounds havin the following Formula;

[00116] Irs some embodiments, at least one eompomid is chosen from compounds havmg the following .Formula:

wherein is chosen from integers ranging from 0 to 250. in some embodiments, p is chosen from integers ranging from 0 to 200. In some embodiments, p is cliosen. from in tegers ranging from 0 to 150, in some embodiments, p is chosen from integers rangin from 0 to 100. in some embodiments, p is chosen from integers ranging from 0 to 50. In some embodiments, p is chosen from integers ranging from 0 to 25. in some embodiments, p is chosen from integers ranging from 0 to 13. in some embodiments, p is chosen from integers ranging from 0 to 10.

|θθ H7] in some embodiments, at least one compound is:

(θθί 18] in some embodiments, at least one compound is chosen from compounds of the foilowins Formulae:

[0 119] Also provided ar phamiaeeuticai compositions comprising at least one compOMnd of Formula (I). Such pharmaceutical compositions are described in greater detail herein. These compounds and compositions may be used in the methods described herein.

[00120| to some embodiments, a method for treating and/o preventing at least one disease, disorder, and/or condition where ' inhibition of E-selectin mediated functions may .he. useful is disclosed, the method comprising administering at least one compound of Formula (i) and/or a pharmaceutical composition comprising at least one compotmd. of Formula fl). j I 21 J In some embodiments, a method for treating and/or preventing at least one inflammatory disease, disorder, and/or condition in which the adhesion and/or migration of cells occurs in the disease, disorder, and/or condition is disclosed, the method comprising administering at least one compound of Formula (I) and/or a pharmaceutical composition comprising at least one compound of Formula (1).

(06122} to some embodiments, a method for inhibiting adhesion of a cancer cell thai expresses a tigand of E-setectin to an endothelial cell expressing E-selectin on the cell surface of the endothelial cell is disclosed, the method comprisin contacting the endodjelial cell and at least one compound of Formula (1) and/or a pharmaceutical composition comprising at least, one compound of Formula (I) such that the at least one compound of Formula (!) interacts with E-selectin on the endothelial cell, thereby inhibitin binding of the cancer cell to the endothelial cell. In some embodiments, the endothelial cell is present in the bone marrow.

(ΘΘ123) In some embodiment, a method for treating and/or preventing a cancer is disclosed, the method comprising administering to a subject in need thereof an. effective amount of at least one compound of Formula (!) and/or a pharmaceutical composition comprising at least one compound of Formula (I). In some embodiments, at least one compound of Fomiula (I) and/or pharmaceutical composition comprising at least one compound of Formula (!) may b administered in conjunction, with as aft adjunct therapy , whic is also, called adjunctive therapy) chemotherapy and/or radiotherapy .

(O0124] The chemotherap and/or radiotherapy may be referred to as the primary antitumor or anti-cancer therapy that is being administered to the subject to treat the particular cancer. In some embodiments, a method for reducing (ie., inhibiting, diminishing) eliemosensitivity and/or radiosensiti vity of hematopoietic stem cells (HSC) to the

chemotherapeutic drug(s) and/or radiotherapy, respectively, is disclosed, the method, comprisin administering to a subject in need thereof an effective amount of at. least one compound of Formula (I) and/or a pharaiaeeirti cal composition comprising at least one compound of Formula (i). [0012S] In some embodiments * a method for enhancing (i.e., promoting) survival of hematopoietic stem cells is provided, the method comprising administering to a subject in need thereof at least cue compound of Formula (I) or a pharmaceutical composition comprising at least one compound of Formula (Ϊ).

[00126] In some embodiments, a method for decreasing the likelihood of occurrence of metastasis of cancer cells (also called tumor cells herein) in a subject who is in need tiiereof is disclosed, the method comprising administering an effective amount of at least one compound of Formula (I) and/or a pharmaceutical composition comprising at least one compound of Form ula (S),

|0012 ] In some embodiments, a method for treatment and/or prevention of at least one cancer in which the cancer cells may leave tire primary site is disclosed, the method

comprising administering, to a subject in need thereof an effective amount of at least, one compound of Formula (I) and/or a pharmaceutical composition comprising at least, one compound of Formula (1). A primary site may be, for example, solid tissue (e.g., breast or prostate) or the bloodstream.

[ΘΘ128) in some embodiments, a method for treatment and/or prevention of at least one cancer in which it is desimble to mobilize cancer cells from a site into the bloodstream and/or retain the cancer cells in die bloodstream is disclosed, the method comprising administering to a subject in need thereof an effective amount of at least one compound of Formula (!) and/or a pharmaceutical composition comprising at least one compound of Formula (I).

[001291 some embodimen ts, a method for decreasing the likelihood of occurrence of infiltration of cancer cells into bone marrow is disclosed, the method comprises administering to a subject in need thereof an effective amount of at least one compound of Formula (I) and/or a pharmaceutical composition comprising at least one compound of Formula (I).

[00130] in some embodiments, a method for releasing cells into circulating blood and enhancing retention of the cells in the blood is disclosed, the method comprising

administering to a subject in need (hereof an effective amount of at least one compound of Formula (I) and/or a pharmaceutical ' composition comprising at least one compound of Formula (I). in some embodiments, the meihod further includes collecting the released cells.. In some embodiments, collecting the released cells utilizes apheresis. In some embodiments, the released cells are stem cells (e.g., ' bone marrow progenitor cells). In some embodiments, G-CSF is administered to the individual.

100131} In some embodiments, a method for treating and/or preventing thrombosis is disclosed, the method comprising administering to a subject in need thereof an effective amount of at least one compound of Formula (I) and/or a pharmaceutical composition comprising at least one compound of Formula (1).

(06 32} In some embodiments, a method for treating and/or preventing mucositis is disdosed, the method comprising administering to a subject in need thereof an effective amount of at least one compound of Formula (I) and/or a pharmaceutical composition comprisin g at least one compound of Formula (1).

(60133} In some embodiments, a compound of Formula (1) and/or a pharmaceutical composition comprising at leas t one compound of Formula (I) may be u sed for the preparation and/or manufacture of a medicament for use in treating and/or preventing at least one of the diseases, disorders, and/or conditions described herein.

(601 4} Whenever a term in the specification is identified as- range (e.g. , CM alkyl), the ran ge independently disc loses and includes each element of the range. As a non-limiting example, CM. alkyl groups includes, independently, A alky! groups, Caalfcyi groups, { ¼ alky! groups, and C alkyl groups,

(00135} The term "at least one" refers to one or more, such as one, two, etc. For example, the term "at least one M alkyl group" refers to one or more CM a!kyl groups, such as one CM alkyl group, two C a!kyl groups, etc.

[60136] The term "alkyl" includes saturated straight, branched, and cyclic (also -identified as cycloalkyi), primary, secondary, and tertiary hydrocarbon groups. Non-limiting examples

feribuit i, eyelobuiyi, l-raethylbutyl, 1,1 -dtmetitylpropyl, pentyl, cyclopenty , isopentyl, neo ' pentyl, cyclopeniyS, hexyl, isohexyl, and cyclohexyL Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted. [00137] The term "aikeayl" includes straight, anched, and cyclic hydrocarbon groups comprising at least one double bond. The double bond of an alkenyl group can be unconjugated or conjugated with another unsaturated group. Non-limiting examples of alkenyl groups include vinyl, alSyi, butenyl, pentenyl, hexenyl, bntadienyl, pentadienyl, hexadienyl, 2-ethy1hexenyl s and cyclopent- 1 -en- 1 -y I . Unless stated otherwise specifically in the specification, an alkenyl group may be optionally substituted,

[0013811 The term ' "alkyn i" includes straight and branched hydrocarbon groups comprising at least one triple bond. The triple bond of an alkynyi group ca be unconjugated or conjugated with another unsaturated group. Non i.miting examples of alkynyi groups include ethynyl propynyL butyayi, petuy«yi,,aud hexynyl. Unless stated- otherwise •specifically in the specification, an . alkynyi group may be optionally substituted.

|ΘΘ13*>) The term "ary " includes hydrocarbon, rin system groups comprising at least carbon atoms an at least one aromatic ring. The aryl group ma be a monocyclic, tricyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Non- limiting examples of aryl groups include aryl groups derived from aceanthrylene, acenaphthyleae, acephenanthrylene, anthracene, azulene, benzene, chrysene, ftuoranthene. fiuorene, av-indacene, v-indaceRe, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and tripiienykne. Unless stated otherwise specifically in the specification, an aryl group may be optionally substituted.

[ΘΘ 40] The term "E-seiectin antagonist" includes inhibitors- f E-seieetia only, as well, as inhibitors of E-seleciin. and either P-selectin or L-seketin, and mhibito s of E-selectiK, P~ seleetin, and L-se ectin.

[ΟΘ1 1] The term "glycomimetic" includes any naturally occurring or non-naturaliy occurring carbohydrate compound in which at least one suhstiiueni has been replaced, or at least one ring has been modified (e.g., substitution of carbon for ring oxygen), to yield a compound that is not fully carbohydrate,

[66142] The term "halo" or "halogen" includes fiuoro, ch!oro, bromo, and iodo,

[.66143] The term f< haioalky1" includes alky! groups, as defined herein, substituted by at least one halogen, as defined herein. Non-lim ng examples of haioalkyl groups include irifiuoromethyj,, difluoromethyl, tricMoromethyi, 2,2 ,2-iri.fiuoroethyl, 1 ,2-difluoroethyL 3-brorao-2-fluoropropyL and i,2 « dibromoethyl. A "fluoroalkyi" is a liaJoalkyl wherein at least one halogen is fluoro. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.

[00144] The term "haioalkeny!" includes alkenyl groups, as defined herein, substituted by at least one halogen, as defined herein. on-limiting examples of haloalkenyl groups include fluoroethenyl, 1.2-dtfluoroef enyl, 3-bromo-2-{luoropropenyl, and 1 ,2-dibroffioethenyl. A "fluoroalkenyl" is a haloalkenyl substituted with at least one fluoro group. Unless stated otherwise specifically in the . specification, a haloalkenyl group may be. optionally substituted,

100145] The term "haloalkynyp includes alkynyl groups, as defined heiein, substituted by at least one halogen, as defined herein. Non-limiting examples include flnoroethynyi,

1,2-difluoroeihynyi, 3-bromo-2-fluoropro ynyl, and 1 ,2-dibromoetfaynyi. A "fiiioroalkynyl" is a haloalkynyl wherein at least one halogen is fluoro. Unless stated otherwise specifically in the specification, a haloalkynyl group may be optionally substituted.

[ΘΘ1461 The term "heteroeycl i" or "heterocyclic ring" includes 3- to 24-raembered saturated or partially unsaturated non-aromatic ring groups comprising 2 to 23 ring carbon atoms and 1 to 8 ring heteroatom(s) each independently chosen from N, ()., and S. Unless stated otherwise specifically in the specification, the heterocyclyl groups may be monocyclic, bicyclie, tricyclic or tetracyclic ring systems, which may include fused or bridged ring systems, and may be partiall or fully saturated; any mtrogen, carbon or sulfur atom(s) in the heierocyclyl group may be optionally oxidized.; any mtrogen atom ¾ the heierocyclyl group may be optionally tpatemized; and the heierocyclyl group .Non- limiting examples of heterocyclic ring include dioxolanyl, thien.y.l l ,3}dithianyl s decahydroiso uinolyl,

imidaxolinyl, imidazolidmyl, isothtaxolidinyl, isoxazolid yl, morphoiinyi octahydroradolyl, octahydroisoindolyl, 2-oxopiperazmyl, 2-oxopiperidinyI, 2-oxopyrrolidtnyl, oxaxolidiiiyl, piperidinyl, piperaztnyl, 4-ptperidonyl, pyrrolidmyl, pyrazolidinyl, quimiclidinyl,

thiazolidinyt, ietrahydrofuryl, trithianyi, tetrahyd pyranyl, thiomorpholinyl, thiamotpholinyi, l-oxo-thiomoipholinyL and IJ -dioxo-t omorpholinyi. Unless stated otherwise specifically in the specification, a heterocyclyl group may be optionally substituted. |0Θ14?] The term "heteroaryf 5 includes 5- to 14-membered ring groups comprising 1 Co 13 ring carbon, atoms and .1 to 6 ring heteroato.m(s) each independently chosen from R O, and S, and at least one aromatic ring. Unless stated otherwise specifically in the specification, the heteroaryi group may be a monocyclic, bicyciic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryi radical may be optionally oxidized; the nitrogen atom may be optionally quatsraized, Non-limiting examples include azepkryi, aeridinyl, benzimidazolyl, benzotliiazoiyi herizindolyt, benzodioxoiyl, benzofuran l, benzooxazol i, benzothiazolyl, benzothiadiazol l, benzoyl l,4)dk xepiuyl 1,4-benzodioxan l, benzonaphiholw nyi, benzoxazolyL benzodioxolyl, benzodioxinyl, benzopyranyJ, benzopyranonyl, benzofuranyl, benzofiirano y}, benzoihienyl (benzothiophenyl), benzotriazol l, benzo 4,6jiniida¾o[ 3. ,2-a]pyridiriyi, carbazolyl, cinnolmyl, dibenz.oftuan l, dibenzotbiophenyl, foranyl, fisranonyl,. isothiazolyl, imldazolyh todaz lyl, indoiyl, indazolyl, isoindolyl, ind.oli.nyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyi, oxadiazolyl, 2-oxoazepinyl, oxazolyl. oxirany.1, l-oxidopyridmyl, 1 -oxidopyrimidmyl, 1 -oxidopytazinyl, 1 -oxidopyridazinyl, 1 -phenyl- lH-pyrrolyl, phenazinyl, phenothiazinyl, ph noxazinyl, phihalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridmyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, qumoxaiinyi, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, tMazolyl, i adiazolyl, tria olyl, tetrazoiyi, iriazinyi and fhiophenyl (i.e. thienyl). Unless stated otherwise specifically in the specification, a heteroaryi group may be optionally substituted.

|ΘΘ1 8 The term "pharmaceutically acceptable salts" includes both acid and base addition salts. Non-limiting examples of pharmaceutically acceptable acid addition salts include chlorides,, bromides, sulfates, nitrates, phosphates, sulfonates, methane sulfonates, formates, tartrates, maieates, citrates, benzoates, salicylates, and ascorbates. Non-limiting examples of pharmaceutically acceptable base addition salts include sodium, potassium, lithium, ammonium (substituted and unsubstituted), calcium., magnesium, iron, zinc, copper, manganese, and aluminum, salts. Pharmaceutically acceptable salts may, for example, be obtained using standard procedures well known in the field of pharmaceuticals. fOOM&l The term "prodrug" includes compounds that may fee converted, for example, under physiological conditions or by solvoiysis, to a biologically active compound described. herein. Thus, the term "prodrug" includes metabolic precursors of compounds described herein that are pharmaceutically acceptable . A discussion of prodrugs can be found, for example, in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol 14, and in Bioreversihie Carriers in Drag Design, ed, Edward B. Roche,

American Pharmaceutical Association and Pergamon Press, 1987. The term "prodrug" also includes covalentl bonded carriers that release the active compound^) as described herein in vivo when such prodrug is administered to a subject. Non-limiting examples of prodrugs include ester and amide derivatives of hydroxy, carboxy, mercapto and amino functional groups in the compounds described herein .

1ΘΘΙ5Θ) The term "substituted" includes the situation where, in any of the above groups, at least one hydrogen atom is replaced by a non-hydrogen atom such as, for example, a halogen atom such as Έ, CI, Br, and I; an oxygen atom in groups such as hydroxy! groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioa!ky! groups, su!fone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, a!kylaraines, dialkykmines, arylamlnes, a!kyLarylamines, diary!ammes, N- oxides, imides, and enamines; a silicon atom in groups such as trialkyisilyl groups, dialky!aryisily! groups, alkyldiarylsi!yl. groups, and triary!silyl groups; and other heteroatoms in various other groups, "Substituted" also includes the situation where, in any of the above groups, at least one hydrogen atom is replaced by a higher-order bond (e.g., a double- or triple-bond} to a heteroatom such as oxygen in oxo, carbonyl, carboxy!, and ester groups; and nitrogen in groups such as imines, oxiraes, hydrazones, and nitriks.

[00151] The present disclosure includes within its scope all the possible geometric isomers, e.g., Z and E isomers (cis and (ram isomers), of the compounds as wel as all the possible optical isomers, ,g., diastereomers and enaniiomers, of the compounds. Furthermore, the present disclosure includes in its scope both the individual isomers and any mixtures thereof, e.g., racemic mixtures. The individual isomers may be obtained using the corresponding isomeric forms of the starting material or they may be separated after the preparation of the end compound according to conventional separation meihods. For the separation of optical isomers, e.g., enantiomers, from the mixture thereof conventional resolution methods, e.g., fractional crystallization, ma be used. [001.52] The present disclosure includes within its scope all possible tautomers.

Furthermore, the present disclosure includes in its scope both the individual tautomers and any mixtures thereof

[00153] Compounds of Formula (I) may be prepared according to the General Reaction Scheme shown in Figure 1. It is understood that one of ordinary' skill in the art may be able to make these compounds by similar methods or by combining other methods known to one of ordinary skill in the art it is also understood that one of ordinary skill in the art would be able to make, in a similar manner as described in Figure 1, other compounds of Formula (Ϊ) not specifically illustrated herein by using appropriate starting components and modifying the parameters of the synthesis as needed, in general, starting components ' ma be obtained from •sources such as Sigma Atdrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCL and Fluorochem USA, etc. and/or synthesized according to sources known to those of ordinary skill in the art (see, for example. Advanced Organic Chemistry: Reactions.,

Mechanisms, and Structure, 5th edition (Wiley, December 2000» and/or prepared as described herein.

[0Θ15 ] It will also be appreciated by those skilled in the art that in the processes described herein the functional groups of intermediate compounds may need to he protected by suitable protecting groups, even if no t specifically described. Such functional groops include hydroxy, amino, mercapto, and carboxylic acid. Suitable protecting groops for hydroxy include but are not limited to trialkylsityl or diaryla!kylsily! (.for example, /-butyldimethylsilyl, t*

boryldiphenylsilyl or trimethytsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include hot are not. limited to /- butoxyearbonyl, ben¾doxycarbonyl and the like. Suitable protecting groups for mercapto include but are not limited to -C(0) " (where R" is alkyl, ary! or arykikyS},

p-methoxybeffiy!, trityl and the like. Suitable protecting group®- for carboxylic acid include but are not limited to alkyl, aryl or ary!alkyl esters. Protecting groups ma be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T. W. and P.G.M. Wiitz, Protective Groups in Organic Synthesis ( 1999). 3rd Ed., Wiley. As one of skill in the art would appreciate, the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2~chk>rooityl-cMoride resin. [00155] Analogous reaciants to those described herein may be identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society. Washington, D.C., may be contacted for more details). Chemicals that are known but not commercially available in catalogs ma be prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services. A reference for the prepara tion and selection of pharmaceutical sa!is of the present disclosure is P. 11 Siahl & C. G. Wermuth "Handbook of Pharmaceutical Salts," Verlag Helvetica

CMmica Acta, Zurich, 2002.

[00156] Methods known to one of ordinary skill in the art ma be identi fied through various reference books, articles, and databases. Suitable reference books and treatise thai detail the synthesis of reaciants useful in the preparation of compounds of the present disclosure, or provide references to articles that describe the preparation, include for example, "Synthetic Organic Chemistry,' 5 John Wiley & Sons, Inc., New York; S. R. Sandler et al,., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1 83; H. O. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T, L, Gilchrist, "Heterocyclic Chemistry", 2nd Ed., John Wiley & Sons, New York, .1992; j. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure," 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatise that detail the synthesis ofreactaats useful in the preparation of compounds of the present disclosure or provide i-eferences to articles: that describe the preparation, include for example, Fuhrhop, J. and Penztin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition 0994) John Wiley <& Sons ISBN: 3-527-29074-5 Hoffman, .V. "Organic Chemistry, An Intermediate Text" (1 96) Oxford University Press, ISBN 0-19-509618-5; Laxock, R. C. "Comprehensive Organic Transformations; A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN: 0-475-19031-4; March, J. "Advanced Organic .Chemistry: Reactions, Mechanisms, and Structure" 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) ^ 'Moder Carho.ny.1 Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1 ; Patai, S. "Patai J s .1992 Guide to the Chemistry of Functional Groups" (1 92) interscience ISBN: 0-471-93022-9; Quin, L.D, et al. "A Guide to Orgaaophosphorus Chemistry" (2000) Wiley -In tersciesice, ISBN; 0-471-31824- 8; Solomons, T. W. G. 'Organic Chemistry * ' 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stoweil J.C., ' ntermediate Organic Chemistry" 2nd Edition (1 93) Wiley- Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmainv s Encyclopedia" (1 99) John Wiley & Sons, ISBN: 3-527-29645- X, in 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, in 73 volumes.

(00157) Biological activity of a compound described herein may be determined, for example, by performing at least one in vitro and/or in vivo, study routinely practiced in the art and described herein or in the art, /» m assays include without limitation bhiding assays, immunoassays, competitive binding assays, and cell based activity assays..

(.00158) An inhibition assay may be used to screen for antagonists of E-selectin. For example, an assay ma be performed to characterize the capability of a compound described herein to inhibit (i.e., reduce, block, decrease, or prevent in a statistically or biologically significant manner) interaction of E-selectin with sLe* or sLe\ The inhibition assay may be a competitive binding assay, which allows the determination of IC«> values. By way of example, E«selectm l.g chimera may be immobilized onto a matrix (e.g., a multi-well plate, which may be made from a polymer,, such as polystyrene; a test tube, and the like); a composition may be added to reduce nonspecific binding (e.g., a composition comprising non-fat dried milk or bovine serum albumin, or other blocking buffer routinely used by a person skilled in the art); the immobilized E-selectin may be contacted with the candidate compound in the presence ofsLe" comprising a reporter group under conditions and for a t me sufficient to permit s.Le a to bind to the immobilized E-selectin; the immobilized E- seleethi may be washed; and the amount of sLe* bound to immobilized E-selec tin may be detected. Variations of such steps can be readily and routinely accomplished by a person of ordinary skill in the art.

(00159) Conditions for a particular assay include temperature, buffers (including salts, cations, media), arid other components that maintain the integrity of any cell used in the assay and the compound, which a person of ordinary skill in the art will be familiar and/or which can be readil determined. A person of ordinary skill in the art also readily appreciates that appropriate controls can be designed and included when performing the in vitro methods and in vivo methods described herein. j I 6f>| The source of a compound that is characterized by at least one assay and techniques described herein and in the art may be a biological sample that is obtained from a subject who has been treated with the compound. The cells that may be used in the assay may also be provided in a biological sample. A "biological sample" may include a sample from a subject, and may be a blood sample (from which serum or piasma may be prepared), a biopsy specimen, one or more body fluids (e.g., lung lavage, ascites, mucosal washings, synovial fluid, urine), bone marrow, lymph nodes, tissue expiani, organ culture, or any other tissue or cell prepara tion from the subject or a .biological Source. A biological sample may further include a tissue or cell preparation .in which the morphological integrity or physical state has been disrupted, for example, by dissection, dissociation, solubilization, fractionation, homogeniza&on, biochemical or chemical extraction, pulverization, lyophilizalion, sonication, or any other means for processing a sample derived from a subject or biological source. In some embodiments, the subject or biological source may be a human or non-human animal, a primary cell culture (e.g.. Immune cells), o culture adapted cell line, including but not limited to, genetically engineered ceil lines that may contain chromosomally integrated or episomal recombinant nucleic acid sequences, immortalized or immortahzable cell lines, somatic cell hybrid cell tines, differentiated or differendatahle cell lines, transformed cell lines, and the like,

|0016l| As described herein, methods lor characterizing E-se lectin antagonists include animal model studies. Non-limiting examples of animal models for liquid cancers used in the art include multiple myeloma (see, e.g., DeWeerdt, Nature 480:S38-S39 (!5 December 201 1) doi: 1 .1038/480S38a; Published online 14 December 2011; Mitsiades et ah, Clin. Cancer Res. 2009 55:1210021 C2009)); acute myeloid leukemia (A t) (Zuber e l, Genes Dev. 2009 April 1; 23(7): 877-889). Animal models for acute lymphoblastic leukemia (ALL) have been used by persons of ordinary skill in the art for more than two decades. Numerous exemplary animal models for solid tumor cancers are routinely used and are well known to persons of ordinar skill in the art. | J62 T he compounds of the present disclosure and the pharmaceutical compositions comprising at least one of such compounds ma be useful in methods for treating and/or preventing a disease or disorder thai is treatable by inhibiting at least one activity of E- selectia (and/or inhibiting binding of E-selectin to a Kgaad, which io turn inhibits a bioiogical activity). Focal adhesion of leukocytes to the endothelial lining of blood vessels is a characteristic step in certain vascular disease processes.

|u¾i63 The compounds of the present disclosure and pharmaceutical compositions comprising at least one such compound may be useful in methods for treating and/or preventing at least on inflammatory disease, inflammation comprises reaction o

vascularized li ving tissue io injury. By way of example, although E-seleetin-mediated cell, adhesion is important to the body's auti-mfective immune response, in other circumstances, E-seiectin mediated cell adhesion may be undesirable or excessive, resulting in tissue damage instead of repair. For example, many pathologies (such as autoimmune and inflammatory diseases, shock and reperfusion injuries) involve abnormal adhesion of white blood cells. Therefore, inflammation, affects blood vessels and adjacent tissues in response to an injury or abnor mal stimulation by a physical, chemical, or biological agent Examples of inflammatory- diseases, disorders, or conditions include, without limitation, dermatitis, chronic eczema, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, graft versus host disease, sepsis, diabetes, atherosclerosis, Sjogren's syndrome, progressi ve systemic sclerosis, scleroderma, acute coronary syndrome, ischemic reperfusion, Crohn's disease, inflammatory bowel disease, endometriosis, glomerulonephritis, myasthenia gravis, idiopathic pulmonary fibrosis, asthma, allergic reaction,, acute respiratory distress syndrome CARDS) or other acute leukocyte-mediated lung injury, vasculitis, or inflammatory autoimmune .myositis. Other diseases and disorders for which the glycomimetk compounds described herein may be useful for treating and/or preventing include hyperacti ve coronary circulation, microbial infection, cancer metastasis, thrombosis, wounds, bums, spinal cord damage, digestive tract mucous membrane disorders (e.g., gastritis, ulcers), osteoporosis, osteoarthritis, septic shock, traumatic shock, stroke, nephritis, atopic dermatitis, f ostbite injury, adult dyspnoea syndrome, ulcerative colitis, diabefcs and reperfusion inj ry following ischaemic episodes, prevention of restenosis associated with vascular s tenting, and for undesirable angiogenesis, for example, angiogenests associated with tumor growth. 6 j As discussed in detail herein, a disease or disorder to be treated, or prevente is a cancer and related metastasis and includes cancers that comprise solid tumor(s) and cancers that comprise liquid iuraor(s). The compounds ofifae present disclosure and pharmaceutical compositions comprising at least one such compound may be useful in methods for

preventing and/or treating cancer. In some embodiments, the ai least one compound may be used for treating and/or preventing metastasis and/or for inhibiting (slowing, retarding, or preventing) metastasis of cancer cells.

(00165) I some embodiments, the compounds of present disclosure and pharmaceutical compositions comprising .at. least one such compound may he used for decreasing (l„, reducing) the likelihood of occurrence of metastasis of cancer cells in an individual (i.e., subject, patient) who. is in need thereof. The compounds of the present disclosure and compositions comprising a least one such compound may be used for decreasing (i.e., reducing) the likelihood of occurrence of infiltration of cancer ceils into bone marrow in an individual who is in need thereof. The individuals (or subjects) in need of such treatments include subjects who have been diagnosed with a cancer, which includes cancers that comprise solid iumor(s) and cancers that comprise liquid iumor(s). f §0166] Non-li.mitfflg examples of cancers include colorectal cancer., li ver cancer, gastric cancer, lung cancer, brain cancer, kidney cancer, bladder cancer, thyroid cancer, prostate cancer, ovaria cancer, cervieal cancer, uterine cancer, endometrial cancer, melanoma, breast cancer, and pancreatic cancer. Liquid tumors can occur in the blood, bone marrow, the soft, sponge-like tissue m the center of most bones, and lymph nodes and include leukemia (e.g., AML, ALL. CLL. and C .L), lymphoma, and. myeloma (e.g., multiple myeloma).

Lymphomas include Hodgkin lymphoma, which is marked by the presence of a type of cell, called the Reed-Steraberg cell, and non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells, Non-Hodgkin lymphomas can be further divided into cancer that have an indolent (slow-growing) course and those that have an- aggressive (fast-growing) course, and which subtypes respond to treatment differently.

|0O!6?J The compounds of the present disclosure and pharmaceutical compositions comprising at least one such compound, may be administered as an adjunct therapy to chemotherapy and or radiotherapy, which is/ar being delivered to the subject as primary therapy for treating the cancer. The chemotherapy and/or radiotherapy that may be administered depend upon several factors including the type of cancer, location of the turaor(s), stage of the cancer, age and gender and general health status of the subject. A person of ordinary skil l in the medical art can readily determine the appropriate

chemotherapy regimen and/or radiotherapy regimen for the subject in need. The person of ordinary skill in the medical art can also determine, with the aid of preclinical and clinical studies, when the compound of the present disclosure or pharmaceutical composition comprising at least one soch compound should he administered to the subject, thai is whether the compound or composition is administered prior to, concurrent with, or subsequent to a cycle of the primary chemotherapy or radiation treatment.

[00168] Also provided herein is a method for inhibiting adhesion of a tumor celi thai expresses a ligand of E-seleetin to an endothelial ceil expressing E-selectin on its cell surface, which method comprises contacting the endothelial cell, with at least one compound of the present disclosure or pharmaceutical compositions comprising at least one such compound, thereby permi ting the compound to interact with E-seleciin on the endothelial cell surface and inhibiting binding of the tumor cell to the endothelial cell. Without wishing to be bound by theory, inhibiting adhesion of tumor cells to endothelial cells may reduce m a significant manner, the capability of the tumor cells to extravasate into other organs, blood vessels, lymph, or bone marrow and thereby reduce, decrease, or inhibi t, or slow the progression of the cancer, including reducing, decreasing, inhibiting, or slowing metastasis.

[ΘΘ169] As described herein, a t least one of the compounds of the presen t disclosure or pharmaceutical compositions comprising at least one soch compound may be administered in combination with at least one additional anti-cancer agent Chemotherapy may comprise one or more chemotherapeutic agents. For example, chemotherapy agents, radiotherapeutic agents, inhibitors of phosphoinositide-3 kinase (PBK), and inhibitors of VEGF ma be used in combination with an E-se ectia antagonist compound described herein. Non-limiting examples of inhibitors of ΡΪ3Κ include the compound named by Exelixis as "XL49 ." Non- limiting examples of VEGF inhibitors include the compound called "cabo" {previously known as XL 184), Many other ehemotherapeuties are small, organic molecules. As understood by a person of ordinary skill in the art, chemotherapy may also refer to a combination of two or more chemotherapeutic molecules that are administered coordinately and which may be referred to as combination, chemotherapy. Numerous chemotherapeutic drags are used in the oncology art and include, for example, alkylating agents;

antimetabolites; anihracyclmes, plant alkaloids: and topoisomerase inhibitors.

[00178] The compounds of the present disclosure or pharmaceutical compositions comprising at least one such compound may function independently from the anti-cancer agent or may function in coordination with the anti-cancer agent, <¾ by enhancing

effectiveness of the anti-cancer agent or vice versa. Accordingly, provided herein are methods for enhancing (i.e., enhancing, promoting, improving the likelihood of, enhancing in a statistically or biologically significant manner) and/or maintaining survival of

hematopoietic stem cells (BSC) in .a subject who is treated with and/Or will be treated with a chemo&erapeuttc drug(s) and/or radioactive therapy ., respectively, comprising .administering at least one E-seJectin antagonist glycomimedc compound as described herein. In some embodiments, the subject receives and/or will receive both chemotherapy and radiation therapy. Also, provided herein is a method for reducing (i.e., reducing, inhibiting, diminishing in a statistically or biologically significant manner) chemosensitivity and/or radiosensittvity of hematopoietic stem cells (HSC) to the chemotherapeutic drugis) and/or radioactive therapy, respectively, in a subject. Because repeated cycles of chemotherapy and radiotlierapy often diminish the abili ty of HSCs to recover and replenish bone marrow, the gjyeomimetie compounds described herein may be useful for subjects who will receive more than one cycle, such as at least two, three, four or more cycles, of chemotherapy and/or radiotherapy. HSCs reside in the bone marrow and generate the ceils that are needed to replenish the immune system and th blood. Anatomically, bone marrow comprises a. vascular niche that is adjacent to bone endothelial sinuses (see, e.g., Kiel et ai, Cell

121:1 109-21 (2005); Sugiyama et ai.. Immunity 25:977-88 (2006); Mendez-Ferrer et ai. Nature 466:829-34 (2010); Butler et at, Cell Stem Cell 6:251-64 (2010». A recent study describes thai E-selectra promotes HSC pro! iteration and is an important component of the vascular niche (see, e.g., Winkler et ai. Nature Medicine published online 21 October 2012; doi:!0.1O38/nm,2969). Deletion or inhibition of E-seiectin enhanced HSC survival in mice thai were treated with chemotherapeutic agents or radiotherapy and accelerated blood neutrophil recovery {see, e.g., Winkler et ai, supra). [00171 ] In addition, the administration of at least one compound of the present disclosure or pharmaceutical composition comprising at least one such compounds may be in

conjunction with one or more other therapies, e.g., for reducing toxicities of therapy. For example, at least one palliative agent to counteract (at least in pari) a side effect of a therapy (e.g., anti-cancer therapy) may be administered. Agents (chemicai or biological) that promote recovery, or counteract side effects of administration of antibiotics or corticosteroids, are examples of such palliative agen ts. At least one E-selectin antagonist described herein may be administered before, after, or concurrently with administration of at least one

additional anti-cancer agent or at least one palliative agent to reduce a side effect of therapy. When administration is concurrent, the combination may be administered from a single container or two (or more) separate containers.

[00172] Cancer celis (also called herein tumor cells) that may be prevented (i.e., inhibited, slowed) from metastasizing, from adhering to an endothelial, cell, or from infiltrating hone marrow include ceils of solid tumors and liquid tumors (including hematological

malignancies). Examples of solid tumors are described herein and include colorectal cancer, liver cancer, gastric cancer, lung cancer, brain cancer, kidney cancer, bladder cancer, thyroid cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, melanoma, breast cancer, and pancreatic cancer. Liquid tumors occur in the blood, bone marrow, and lymph nodes and include leukemia (e.g., AML, ALL, CLL, and CML), lymphoma (e.g., Hodgkiji lymphoma and non~Hodgkin lymphoma), and myeloma (e.g. , multiple myeloma). As used herein, the term cancer cells include mature, progenitor, and cancer stem cells.

|ΘΘΊ73| Bones are a common location for cancer to infiltrate once leaving the primary tumor location. Once cancer resides in bone, it is frequently a cause of pain to the individual. In addition, if the particular bone affected is a. source for production of blood cells in the hone marrow, the individual may de velop a variet of blood cell related disorders . Breast and prostate cancer are examples of solid tumors that migrate to bones. Acute myelogenous leukemia (AML) and multiple myeloma (MM) are examples of liquid tumors that migrate to bones. Cancer cells that migrate to bone will typically migrate to the endosteal region of the bone marrow. Once cancer ceils have infiltrated into the marrow, the cells become quiescent and are protected from chemotherapy. The compounds of the present disclosure block infiltration of disseminated cancer cells into bone marrow.. A variety of individuals may benefit from treatment with the compounds. Examples of such individuals include individuals with a cancer type having a propensity to migrate to bone where the tumor is still localized or the tumor is disseminated but not yet infiltrated bone, or where individuals with such a cancer type are in remission.

|ΘΘ174) The cancer patient population most likely to respond to treatment using the E- selectin antagonist agents (e.g., compounds of Formula (I)) described herein can be identified based on the mechanism of action of E-selectin. That is, patients may be selected that express a highly active E-selectin as determined by the genetic polymorphism for E-selectin of SI 28 ' (Alessandro et I., . J, Cancer ./2 :52S-535, 2007). in addition, patients for treatment by the compounds described herein may also selected based on elevated expression of the E-selectin binding Sigands (sialyl Le a and sialyl Le x ) as determined by antibodies directed against cancer-associated antigens CA-1.9-9 (Zheng et al., World J. Gastroenterol. 7:431-434, 2001 ) and CD65. In addition, antibodies HECA-452 and FH-6 which recognise similar carbohydrate Sigands of .E-selectin may also be used in a diagnostic assay to select the cancer patient population most likely to respond to this treatment. fi>0175] The compounds of the present disclosur and pharmaceutical compositions comprising at least one such compound may be useful, in methods for treating andfor preventing thrombosis, As described, herei methods are provided fo inhibiting formation, of a thrombus, or inhibiting the rate at which a thrombus is formed.. These methods may therefore be used for preventing thrombosis {l.e. t reducing or decreasing the likelihood of occurrence of a thrombus in a statistically or clinically significant manner).

[00176] Thrombus formation may occur in infants, children, teenagers and adults. An individual may have a hereditary predisposition to thrombosis. Thrombosis ma be initiated, for example, due to a medical condition (such as cancer or pregnancy), a medical procedure (such as surgery) or an environmental condition (such as prolonged immobility). Other individuals at risk for thrombus formation include those who have previously presented with a thrombus.

[00177] The compounds of the present disclosure and pharmaceutical compositions comprising a least one such compound ma be useful in. methods for treating individuals undergoing thrombosis or who are at risk of a thrombotic event occurring. Such individuals may or may not have a risk of bleeding, in some embodiments, the individual has a risk of bleeding. In some embodiments, the thrombosis is a venoas thromboembolism (VTE). VTE causes dee vein thrombosis and pulmonary embolism. Lo molecular weight (LMW) heparin is the current mainstay therapy for the prevention and trea tment of VTE. In many circumstances, however, the use of LMW heparin is contraindicated. LMW heparin is a known anti-coagulant and delays clotting over four times longer than control bleedin times. Patients undergoing surgery, patients with thrombocytopenia, patients with a history of stroke, and many cancer patients should avoid administration of heparin doe to the risk of bleeding. By contract, administration of the E~seleciin antagonist compounds of Formula (I) significantly reduces the time to clotting than occurs when LMW heparin is administered, and thus provide a significant improvement in reducing bleeding time compared with LMW heparin,. Accordingly, the compounds and pharmaceutical compositions described -herein may not. only be useful for treating a patient for whom the risk of bleeding is not significant, but also may be useful in when the risk of bleeding is significant and the u se of anti- thrombosis agents with anti-coagulant properties (such as LMW heparin) is contraindicated.

(00178J The compounds of the present disclosure and pharmaceutical compositions comprising at least one soch compoond may be administered in combination with at least one additional anti-thrombosis agent. The compounds of the present disclosure and

pharmaceutical compositions comprising at least one soch compoond may junction independently from the anti-thrombosis agent or may function in coordination with the at l east one . anti-thrombosis agent In addition , the administration of one or more of the compounds or compositions may be in conjunction with one or more other therapies, e ., for reducing toxicities of therapy. For example,, at least one palliative agent to counteract (at least in part a side effect of therapy may be administered. Agents (chemical or biological) that promote recovery and/or counteract side effects of administration of antibiotics or corticosteroids are examples of such palliative agents. The compounds of the present disclosure and pharmaceutical composition comprising at least one such, compound may be administered before, after , or concurrently with administration of at least one additional anti- thrombosis agent or at least one palliative agent to reduce a side effect of therapy. Where administration is concurrent, the combination may be administered from a single container or two (or more) separate containers. j I 79] The compounds of the present disclosure and pharmaceutical compositions comprising at least one such compound may be useful in methods for preventing and/or treating mucositis. In some embodimen ts, at least one compound of Formula (1) or a pharmaceutical composition comprising at least one compound of Formula (I) may be used in methods described herein for decreasing the likelihood of occurrence of mucositis in a subject who is in need thereof by administering the compound or composition to the subject. In some embodiments, the mucositis is chosen from oral my in ' * esophageal mucositis, and gastrointestinal mucositis, hi some embodiments, the mucositis is alimentary mucositis,

|ΘΘ180 It is believed that approximately half of all cancer patients undergoing therapy suffer some degree: of mucositis. Mucositis ' is believed to occur, for example, in virtually all patients treated with radiation therapy for head and neck tumors, all patients receiving -radiation along the Gi tract, and approximately 40% of those subjected to radiation therapy and/or chemotherapy for tumors in other locations (e.g., teukemias or lymphomas). It is also is believed to be highly prevalent in patients treated with high close chemotherapy and/or irradiation for the purpose of myeloablation, such as in preparation for stem cell or bone marrow transplantation. The compounds of the present disclosure and pharmaceutical compositions comprising at least one such compound, may be useful in methods for treating and/or preventing mucositis in a subject afflicted with cancer, in some embodiments, the subject is afflicted with a cancer chosen from head and neck cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, lymphatic cancer, leukemic cancer, and/or gastrointestinal cancer. In some embodiments, the mucositis is associated with radiation therapy and/or chemotherapy, in some embodiments, the chemotherapy comprises administering a therapeutically effective amount of at least one compound chosen from platinum, cisplaim, carboplatin,. oxalip ' iatin, mechloretbatnine, cyclophosphamide,

chlorambucil, azathiopriiie, mereaptopurine, vincristine, vinblastine;, vinorelbine, vindesine, etoposide, tenyposide, paciitaxei, docetaxel mnotecan, !opotecari, amsacrine, etoposide, etoposide phosphate, teniposide, 5-fl.uorouracil (5-FlJ), leucovorin. methotrexate,

gemciiabme, iaxane, leucovorin, mitomycin C, tegafur-uracil idambicin ,fludarabine, miioxantrone, ifosfamide and doxorubicin. [00181] In some embodiments * the method further comprises administering a

therapeutically effective amount of at least one MMP inhibitor, inflammatory cytokine inhibitor, mast cell inhibitor, SAID, NO inhibitor, or antimicrobial compound.

|00182] in some embodiments, the method further comprises administering a

therapeutically effective amount of velafermin and/or palifermm.

|ΘΟί83] The compounds of the present disclosure and pharmaceutical compositions comprising at least one such compound may be useful in methods for mobilizing cells ' from the bone marrow to the peripheral vasculature and tissues. As discussed herein, in some embodiments, the compounds and compositions are useful for mobilizing hematopoietic cells, including hematopoietic stem cells and hematopoietic progenitor cells. In some embodiments, the compounds act as mobilizin agents of normal blood ceil types. In some embodiments, the agents are used in methods for mobilizing mature white blood cells (which ma also be called leukocytes -herein),, such as granulocytes (e.g., neutrophils, eosinophils, basophils), lymphocytes, and monocytes from the bone marrow or other immune cell compartments such as the spleen and liver. Methods are also provided for using the compounds of the present disclosure and pharmaceutical compositions comprising at least one such compound in methods for mobilizing tumor ceils from the bone marrow. The tumor cells may be malignant cells (e.g., tumor cells that are metastatic cancer cells, or highly invasive tumor cells) in cancers. These tumor cells may be of hematopoietic origin or may be malignant cells of another origin residing in the bone .

[00184] In some embodi ments, the methods using the E-selectiii antagonists described herein are useful for mobilizing, hematopoietic cells, such, as hematopoietic stem cell ' s and. progenitor ceils and. leukocytes (including granulocytes such as neutrophils), which are collected (i.e., harvested, obtained) from the subject receiving the E-selectin antagonist and at. a later time are administered back into the same subject (autologous donor) or administered to a different subject (allogeneic donor). Hematopoietic stem cell replacement and

hematopoietic stem cell transplantation have been successfully used for treating a number of diseases (including cancers) as described herein and in the art. By way of example, stem ceil replacement therapy or transplantation follows myeloablation of a subject, such as occurs with administration of high dose chemotherap and/or radiotherapy. Desirably, an allogeneic donor shares sufficient HLA antigens with the recipient subject to minimize the risk of host versus graft disease hi the recipient (i.e., the subject receiving the hematopoietic stem ceil transplant). Obtaining the hematopoietic cells from the donor subject (autologous or

allogeneic) is performed by apheresis or !eukapheresis. HLA typing of a potential donor and the recipient and apheresis or leukapheresis are methods routinely practiced in the clinical art,

(ΘΘ185) By way of non-limiting example, autologous or allogenic hematopoietic stem cells and progenitors ceils may be used for treating a recipient subject who has certain cancers, such as Hodgkin lymphoma, non-Hodgkin lymphoma, or multiple myeloma. Allogeneic hematopoietic stem cells and progeni tors ceils ma be used, for example, for treating a recipient subject who has acute ieukemias {e.g., AML, ALL)' chronic lymphocytic leukemia (CLL); ai¾egakaryocytosis congeaital thrombocytopenia; aplastic aneniia fefractaty anemia; familial erythrophagocytic lymphohistioeyiosis; myelodysplastic syndrome/other

myelodysplastic disorders; osteopetrosis; paroxysmal nocturnal hemoglobiriuria; and

Wiskoit-aidrich syndrome, for example. Exemplary uses for autologous hematopoietic stem cells and progenitors cells include treating a recipient subject who has amyloidosis; germ eel! tumors (e.g., testicular cancer); or a solid tumor. Allogeneic hematopoietic stem cell, transplants have also been investigated for use in treating solid tumors (see, e.g., Ueno et ah, Biood 102:3829-36 (2003)).

(00186] In some embodiments o f the methods described herein, the subject is not a donor of peripheral hematopoietic cells but has a disease, disorder, or condition for which

mobilization of hematopoietic ceils in the subject will pro vide clinical benefit. Stated another way, while this clinical situation is similar to autologous hemato oietic ceil replacement, the mobilized hematopoeitic cells are not removed and given back to the same subject, at a later time as occurs, for example, with a subject who receives myeloablation therapy. Accordingly; methods are. provided for mobilizing hematopoietic cells, such as hematopoietic stem cells and progenitor cell and leukocytes (including granulocytes, such as neutrophils), by

administering at least once compound of Formula (1). Mobilizing hematopoietic stem cells and progenitor cells may be useful for treating an inflammatory condition or for tissue repair or wound healing. See, e.g., imeault et ai., Clin. Pharmacol Therapeutics 82:252-64 (2007). [00187] In som embodiments,, the methods described herein are useful for mobilizing hematopoietic leukocytes (white blood cells) in a subject, which, methods may be used in treating diseases, disorders, and conditions for which an increase in white blood cells, such as neutrophils, eosinophils, lymphocytes, monocytes, basophils, will provide clinical benefit. For example, for cancer patients, the compounds of Formula (!) are beneficial for stimulating neutrophil production to compensate for hematopoietic deficits resulting from chemotherapy or radiation therapy. Other diseases, disorders, and conditions to be treated include infectious diseases and related conditions, such as sepsis. When the subject to whom at least one compound of Formula (I) is administered is a donor, neutrophils may be collected for administration to a recipient subject who has reduced hematopoietic function, reduced immune function, reduced neutrophil count, reduced neutrophil mobilization, severe chronic neutropenia, leucopenia, thrombocytopenia, anemia, and acquired immune deficiency syndrome. Mobilization of .mature white: blood cells may be useful in subjects to improve- or to enhance tissue repair, and to minimize or prevent vascular injury and tissue damage, for example following liver transplantation., myocardial infarctio or limb ischemia. See, e.g., Pe us, Curr. Opin. Hematol. 15:285-92 (2008); Lemoii et al., Haematohgic 93:321-24 (2008).

[00188] The compound of Formula (1) may be used in combination with one or more other agents that mobilise hematopoietic cells, Such agents include, for example, G-CSF;

AMD3100 or other CXCR4 antagonists; GRO-β (CXCL2) and an -temiinai 4-a.tiiino truncated form {88-251353); lL-8SDF-ia peptid analogs, CTCE-0021 and CTCB-0214; and the SDF 1 analog, Met-SDF-lfi (see, e.g., Pelus, supra and references cited therein). I some embodiments, a compound of Formula (Ϊ) may be administered with othe mobilizing agents used in the art, which may permit administration of a lower dose of GCSF or AMD31 0, for example, than required in the absence of a compound of Formula (I). The appropriate therapeutic regimen for administering a compound of Formula (I) in combinat ion with another mobilizing agent or agents can be readily determined by a person skilled in the clinical art

[00189] The terms, "treat" and "treatment," include medical management of a disease, disorder, and/or condition of a subject (i.e., patient, individual) as would be understood by a person of ordinary skill in the .(see, e.g., Stedman's Medical Dictionary). In general, an appropriate dose and treatment regimen provide at least one of the compounds of the present disclosure m aa amount sufficient to provide therapeutic and/or prophylactic benefit. For both therapeutic treatment and prophylactic or preventative measures, therapeutic and/or prophylactic beoefit includes, for example, an improved clinical outcome, wherein the object is to prevent or slow or retard (lessen) an undesired physiological change or disorder, or to prevent or slow or retard (lessen) the expansion or severity of such disorder. As discussed herein, beneficial or desired cliiiicai results from treating a subject include, but are not limited to, abatement, lessening, or alleviation of symptoms that result from or are associated with the disease, condition, and/or di sorder to be treated; decreased occurrence of symptoms; improved quality of life; longer disease-free status ( ._?., decreasing the likelihood or the propensity that a subject will present symptoms on the basis of which a diagnosis of a disease is made); diminishment of extent of disease; stabilized (i.e., not worsening) state of disease; delay or slowing of disease progressioii; amelioraiioft or palliation of the disease state; and remission (whether partial or total), whether detectable or undetectable; and/or overall survival. "Treatment" can include prolonging survival when compared to expected survival if a subject were not receiving treatment.

100198] in some embodiments of the methods described herein, the subject is a human, in some embodiments of the methods described herein, the subjec is a non-human animal . Non-human animals that may be treated include mammals, for example, non-human primates (e.g., monkey, chimpanzee, gorilla, and the like), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), iagomorphs, swine (e.g., pig, miniature pig), equine, canine, feline, bovine, and other domestic, farm, .and zoo animals;

[0019:1 ) The effectiveness of the compounds of the present disclosure in treating and/or preventing diseases, disorders, and/or conditions treatable by inhibiting an activity of E- selectin can readily be determined by person of ordinary skill in the rele vant art.

Determining and adjusting an appropriate dosing regimen (e.g., adjusting the amount of compound per dose and/or number of doses and frequency of dosing) can also readily be performed by a person of ordinary skill in the relevant ait. One or any combination of diagnostic methods, including physical examination, assessment and monitoring of clinical symptoms, and performance of analytical tests and methods described herein, may be used for monitoring the health status of the subject. [00192] Also provided herein are pharmaceutical compositions comprising at least one compound of Formula (1). in some embodiments, the pharmaceutical composition further comprises at least one additional pharmaceutically acceptable ingredient,

[00193] 1B pharmaceutical dosage forms, any one or more of the compounds of the present disclosure may be administered in the form of a pharmaceutically acceptable derivative, such as a salt, and/or it or they may also be used alone and/or in appropriate association, as well as in combination, with other pharmaceutically active compounds,

[00194] An effective amount or therapeutically effective amount refers to an amount of at least one compound of the present disclosure or a pharmaceutical composition comprising at least one suc compound that, when administered to a subject, either as a single dose or as part of a series of doses, is effective to produce at !east one therapeutic effect. Optimal doses may generally be determined using -experimental models and or clinical trials. Design and execution of preclinical and clinical studies for each of the therapeutics (i ncluding when administered for prophylactic benefit) described herein are well within the skill of a person of ordinary sk.il! in the relevant art. The optimal dose of a therapeutic may depend upon the body mass, weight, and/or blood volume of the subject. In general, the amount of at least one compound of Formula (I.) as described herein, that is present in a dose, may range from about: 0.01 itg to about 3000 ug per kg weight of the subject. The minimum dose that is sufficient to provide effective therap may be used in some embodiments. Subjects may generally be monitored, for therapeutic effectiveness using assays suitable for the disease, disorder and/or condition being treated or prevented, which assays will be familiar to those having ordinary skill in the art and are described herein. The level of a compound that is administered to a subject ma be monitored by determining the level of the compound (or a metabolite of the compound) in a biological fluid, for example, in the blood, blood fraction (e.g., serum), and o in the urine, and/or other biological sample from the subject. An method practiced in the art to detect the compound, or metabolite thereof may be used to measure the level of the compound during the course of a therapeutic regimen.

[ΘΘ195Ι The dose of a compound described herein may depend upon the subject 's condition, that is, stage of the disease, severity of symptoms caused by the disease, general health status, as well as age, gender, and weight, and other factors apparent to a person of ordinary skill in die medical ait. Similarly, the dose of the therapeutic for treating a disease, disorder, and/or condi tion may be determined according to parameters understood by a person of ordinary skill the medical art.

[00196] Pharmaceutical compositions may be administered in any manner appropriate to the disease, disorder, and/or condition to be treated as determined by persons of ordinary skii! in the medical arts. An appropriate dose and a suitable duration and frequency of

administration will be determined by such factors as discussed herein, including the condition of the patient, the type arid severity of the patient's disease, the particular form of the acti ve ingredient and the method of dministtation.. in general, an appropriate dose (or effectiv dose) and treatment regimen provides the com ositio ' ) as described herein in an amount sufficient to provide therapeutic and/or prophylactic benefit (for example, an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or o verall survival or a lessening of symptom severity or other benefit as described in detail above). f ΘΘ 197] The pharmaceutical compos) Lions described herein may be administered, t a subject in need thereof by any one Of several routes that effectively delivers an effective amount of the compound. Non-limiting examples of suitable administrative routes include topical, oral, nasal, intrathecal, enteral, buccal, sublingual, transdermal, rectal, vaginal, intraocular, subconjunctival, subungual, and parenteral adniinistmti.au., including

subcutaneous, intravenous, intramuscular., intrastemal, intraeavernous, intrameatal, and. intranrethrai injection and or infusion.

|ΘΘΙ98{ The pharmaceutical compositions described herein may, for example, be sterile aqueous or sterile non-aqueous solutions, suspensions, or emulsions, and may additionally comprise at least one pharmaceutically acceptable excipient (Le., a non-toxic material, that does not interfere with the activity of the active ingredient). Such compositions may, for example, be in the form of a solid, liquid, or gas (aerosol). Alternatively, the compositions described herein may, for example, be formulated as a lyophilizate, o compounds described herein may be encapsulated within liposomes using technology known in the art. The pharmaceutical compositions may further comprise at least one additional pharmaceutically acceptable ingredient, which may be biologically active or inactive. Non-limiting examples of such ingredients include biiffei's (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, maunose, sucrose or dextrans), man tol, proteins, polypeptides, amino acids (e.g., glycine), antioxidants, chelating agents (e.g., EDTA and glutathione), stabilizers, dyes, flavoring agents, suspending agents, and preservatives.

|00I9 | Any suitable excipient or carrier known to those of ordinary skill in the art for use in compositions may be employed in the compositions described herein. Excipiems for therapeutic use are well known, and are described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, l sl Ed. Mack Pub. Co., Easton, PA (2005)}. In general, th type of excipient may be selected based on the mode of administration.,, as well as the chemical composition of the active ingredient(s). Compositions may be formulated for the particular mode of administration.. For parenteral administration, pharmaceutical

compositions may further comprise water, saline, alcohols, fats, waxes, and boifers. For oral administration, pharmaceutical compositions may further comprise at least one component chosen, for example, from any of the aforementioned ingredients, excipients and carriers, such as manniiol, lactose, starch, magnesium s!earate, sodium saccharine, talcum, cellulose, kaolin, glycerin, starch dextrins, sodium alginate, car oxymethylceilulose, ethyl cellulose, glucose, sucrose, and magnesium carbonate.

{OO2O0| The pharmaceutical compositions (e.g., for oral administration or delivery by injection) may be in the form of a liquid. A liquid composit ion may include, for example, at least one the following: a sterile diluent such as water for injection, saline solution, including for example physiological saline. Ringer's solution, isotonic sodium chloride, fixed oils that may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents; antioxidants; chelating agents; buffers and agents for the adjustment of tonicity such as sodium chloride or dextrose. A parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. In some embodiments, the pharmaceutical composition comprises physioiogical saline. Jn some embodiments, the pharmaceutical composition is an injectable composition, and in some embodiments, the injectable composition is sterile.

|ΘΘ2Θ1) For oral formulations, at least one of the compounds of the present disclosure can be used alone or in combination with at least one additive appropriate to make tablets. powders, granules and/or capsules, for example, those chosen from conventional additives, disintegrators, lubricants, diluents, buffering agents, moistening agents, preservatives, coloring agents, and flavoring agents. The pharmaceutical compositions may be formulated to include at least one buffering agent, which may pro vide for protection of the active ingredient from low E of the gastric environment and/or an enteric coating. A

pharmaceutical composition may be formulated for oral delivery with at least one flavoring agent, e.g., in a liquid, solid or semi-solid formulation and/or with an enteric coating.

(ΘΘ202) Oral formulations may be provided as gelatin capsules, which may contai the active compound or . iological along with, powdered carriers. Similar carriers and diluents may be used to make compressed tablets. Tablets and capsules can be .manufactured as sustained release products to provide for continuous release of active ingredients over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

|002©31 A pharmaceutical composition may be formulated for sustained or slow release. Such compositions may generally be prepared using well known technology and

administered by, for example, oral, rectal, or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain the active therapeutic dispersed in a carrier matrix and/or contained within a reservoir -surrounded, by a rate controlling membrane.. Excipients for use within, such formulations are biocompatible, and. may also be biodegradable; the formulation may provide a relativel constant level of active component release. The amount of active therapeutic contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release, and the nature of the condition to be treated or prevented,

|002i4] The pharmaceutical compositions described herein can be formulated, as

suppositories by- mixing with a variety of bases such as emulsifying bases or water-soluble bases. The pharmaceutical compositions may be prepared as aerosol formulations to be administered via inhalation. The pharmaceutical compositions may be formulated into pressurized acceptable propeilants such as dichlorodifluoromethane, propane, nitrogen and the like. |002 S| T he compounds of the present disclosure and pharmaceutical compositions comprising these compounds may be administered topically (e.g., by transdermal

administration). Topical formulations may he in the form of a transdermal atch, ointment, paste, lotion, cream, gel, and the like. Topical formulations may include one or more of a penetrating agent or enhancer (also call permeaiion enhancer), thickener, diluent, emaisifier, dispersing aid, or binder. Physical penetration enhancers include, for example,

electrophoretic techniques such as iontophoresis, use of ultrasound (or "phonophoresis"), and the like. Chemical penetration enhancers are agents administered either prior to, with, or immediately following administration of the therapeutic, which increase the permeability of the skin, particularly the stratum corneum, to provide for enhanced penetration of the drug through the skin. Additional chemical and physical penetration enhancers are described in, for example. Transdermal Deliver)'' of Drags, A. P. Kydomeus ( ED) 1987 C L Press;

Percutaneous Penetration Enhancers,, eds. Smith et al, (C C Press, 1995); Lenneras et al, J Pharm. Pharmacol. 54:499-508 (200:2); Karande et al, Pharm. Res. 19:655-60 (2002); Vaddi et al, Int. . Pharm. 91 :1639-51 (2002); Venturis et al, J Drug Target 9:379-93 (2001); Shokri et al. Int. J, Pharm, 228{ l-2);99-107 (2001); Suzuki et al, Biol Pharm, Bull. 24:698- 700 (2001); Alberti et al, J. Control Release 71 :319-27 (2001); Goldstein et al. Urology 57:301-5 (2001); iijavainen et al, Eur, J. Pharm. Set 10:97-102 (2000); and Tenjaria et al. Int. J, Pharm, 192:147-58 (1 99).

[ 2 ] Kits comprising unit doses of at least one compound of the present disclosure, for example in oral or injectable doses, are provided. Such kits may include a container comprising the unit dose, an informational package inser describing the use and attendant benefits of tire therapeutic in treating the pathological condition of interest, and/or optionally an appliance or device for delivery of the at least one compound of Formula (I) and/or pharmaceutical composition comprising the same.

EXAMPLES

EXAMPLE 1: COMPOUND 11

(0Θ207] .Compound 2: A solution of I-f (l-oxo-2-propynyl)oxyl-2 J 5-pyrrOlidinedi (propargylic acid NHS ester) (57 nig, 0,34 mrnole) in anhydrous DMF (1 m ' L) was added dropwise o ver 15 minutes to a slurry of compound 1 (0.19 g, 0.26 mole) (preparation described in WO 20 3096926) and DIPEA (0.1 mL) in anhydrous DMF (3 mL) at room temperature. The resulting solution was stirred for 1.5 hrs. The reaction mixture was

concentrated under reduced pressure, The residue was separated by Combi-flash

BtOAe/(MeOH/water, 6/1, /v), 9/1 - 3/7, v/v] to afford the desired compound as a light brown solid (0.14 g„ 69%). MS; Calculated for CSTMJSNJOJS ~ 785.3, Found ES- ositive mlz ===808.3 (M+Na"), ES-negative m z ^ 784.4 (M-l).

4

[0020S] Comp iind 4: To a solution of componnd.3 (preparation described in WO

2013096926) (2.5 g, 3.54 mmole) and DIPEA (1.2 m ' L, 7.08 mmole) in anhydrous DMF ( 15 mL) was added TSTU (1.7 g, 5.31 mmole) at 0 *C and the solution was stirred for 20 mm. Azetidine (0,85 mL, 35,4 mmole) was added and the resulting solution was stirred for 1 hr while the temperatare was gradnaliy increased to room temperatare. After the reaction was completed, the solution was concentrated under reduced pressure. The reaction mixture was separated by Combi-flash (BtOAc/MeOH, 4/1-2/3, v/v) to give compound 4 (1 , Ϊ 7 g, 1.57 mmole, 44%) and lactone side product compound 5 (0,88 g, 1,28 mmole, 36%).

(ΘΘ209] Compound 4; Compound 5 (0,88 g, 1 ,28 nimol) was dissolved in anhydrous

DMF (5 mL). Azetidine (0,5 mL) was added, and then the resulting solution was stirred for hrs at 50 °C, The solution was concentrated and dried under high vacuum to give compound 4 (0,93 g, 1.25 mmole, 98%).

100210} ¾ (4O0 MHz, Deuterium Oxide) § ' 4,92 (d, - 4.0 H¾ 1 H), 4.79 (q, J ~ 7,3 , 6.8 Hz, 1H , 4,43 (broad d, J - 8.3 H¾ ? 1 H), 4.24 (q, J - 8.6 Hz, ! H), 4, 15 <q, J - 8.5 ¾ IH), 4.01 (d, J ■■■■■■■ 9.3 Hz, 1 H), 3,99 - 3.80 Cm, 3H), 3.76 (dd, J - 10.6, 3.2 Hz, 1 H), 3.73 ~ 3.51 (m, 8H), 3.42 im, J= 7.7, .4 Hz, 2H), 3.21 (t, J === 9.7 Hz, IH), 2.39 (broad t, J** 12.7 Hz, IH), 2.32 - 2.09 (m, 3H), 1.95 (s, 3.H), 1.95 (ra, .1 H)5.77 (m, 2H), 1.69 - 1.35 (m, 7H), 1.35 - 0.93 (m, I OH), 0,93 ~ 0,5 (m, 6H). MS; Calculated for C¾H6oN 2 O w » 785.3, Found ES- positive m/z -767.3 (M÷Na * ), ES-negative m ~ 743.4 (M-l).

6

(ΘΘ211) Compound 6: A soiuiion of compound 4 (0.93 g, Ϊ .25 mmoie) in ethylene diamine (10 mL) was stirred overnight at 60 f' C. The solution was concentrated under reduced pressure and the residue was directly purified by silica gel column chromatography

(EtOAc/MeOH, 1 /2, v/v) to give compound 6 as a light yellow gel (0.9 g, 1 , 16: mmoie, 1 ). MS: Calculated for CsrHs + aOjj - 772,4, Foun ES- positive m/z -773.4 (M+i!-f ).

7

[00212) ompound 7: A solution of compound 6 (0.22 g, 028 mmoie) and 3 drops of DiPEA m anhydrous DMF (3 mL) was cooled to 0 "C. Propargylic acid NHS ester (57 nig, 0.34 mmoie) was slowly added. The resulting solution was stirred for I hr. The solution was concentrated under reduced pressure and the residue was directly purified by Combi-fiash I EtOAc/(MeOH/water, 6/1 , v v), 1/9-2/8, v/v). The product lyophiiized to give compound 7 as an off-white solid (0.12 g, 0.1.5 mmoie, 54%). MS: Calculated for C^OMOn = 824.4, Found ES- positive m/z =847.3 (M+Na " ).

[00213] Compound 9: To a slurry soiuiion of compound 1 (0.1.2 g, 0.16 mmoie) and DIPEA (0.1 mL) in anhydrous DMF ( i mL) was added a solution of azidoacetic aoid-NHS ester (compound 8) (39 mg, 0,2 mmoie) in anhydrous DMF (1 mL) dropwise over a 10 minute period at room temperature. The resulting solution was stirred for 3hrs. The reaction mixture was concentrated under reduced pressure and the residue was purified by Combi- flash eluting with [EtOAc/CMeOH waier, 6/1 , v/v), 9/1 - 2/8, v/v]. The product was collected then iyophiiized to give compound 9 as a white solid (0.11 g, 0.13 mmoie, 81%). MS: Calculated for ΟπΗ^Ν^Ου·- 816.4, Found ES- positive m z -838.7 (M+Na ' ) > ES- negative m/z =814.7 (M~H).

[00214] Compound 11: A solution of PEG- 17 Bis-NHS ester (compound 10} (0.2 g, 0.1 mmol) in DMSO (2 roL) was added to a solution of compound 1 (0.4 g, 0.56 ramole) and DIPEA (0.2 ml , } in anhydrous DMSO (2 mL) dropwise over a 5 minute period at room temperature. The resulting solution was stirred overnight. The solution was dialyzed against distilled water for 3 days with dialysis tube MWCO 1000 while distilled water was changed every 12 hours. The solution in the tube was lyophilized overnight to give compound 11 as a white solid (032 g, 0.14 mmoje, 77%).

100215] 1.H NMR (40 MHz, Deuterium Oxide) δ 5.02 (d, J = 3. Hz, 2H) 5 4.90 (¾ J = 6.7 Hz, mi 4.52 (broad d, I = 8.4 Hz, 2H), 3.97 (broad i, 2H), 3.86 - 3.74 (m, 16H), 3.73 - 3.59 (m, 62H), 3.56 (t, J - 5.8 Hz 2H), 3.44 (m, 2H), 3.34-3.26 (m, 10H), 2.50 (L J - 6.1 Hz 4H), 2.31 (broad t, 2H), 2.J 2 (m, 2B), 2.04 (s, 6H), 1.90 - 1.79 (m, 4H), 1.78 - 1.38 (oi, 14H}, 1.37 - J .26 (m, I4H), 1.25 - 1.08 (m, 14H), 0.98 - 0.79 (m, lOH). MS: Calculated for CiosHtssNeO,? = 2297.2, Found MALDl-TOF m/z = 2321, (M+Na * ).

EXAMPLE 2: COMPOUND 12

{00216] ' Compound 12; Prepared in an analogous manner from compound 1 and PEG-25 bis-NHS ester.

{«0217] 1H NMR (400 MHz, Deuterium Oxide) δ 5.03 (d s J- 3.9 ¾ 2fi), 4.91 6.9 Hz, 2H), 4.53 (broad d, J~ : 8.4 Hz, 2H), 3.98 (broad t, J * 8.8 H¾ 2H), 3.92-3.86 (a, 6H) 5 3.81 - 3.7 -(is, 2H) f 3.78 - 3.74 (m, 4H), 3.72 - .66 (511, ! øø¾ 3.56 (L J - 5.7 Hz . 2H)„ 3.52 - 3.40 (m, 2H), 3.37-3.25 (ro, lOH), 2.53 -2.49 (t, J - 6.1 Hz 4H), 2.31 (m, 2H), 2.16 - 2.13 (m 5 2B) 5 2,05 (s 5 6H), 1.86 - 1.84 (m, 4H), 1.76 - 1.65 (m, 4H),1.63 - 1.44 (m, 1 OH), 1.41 - 1.29 (m, 14H), 1.27 - .1.12 (m, ! 4H), 0.94 - 0.89 (m, 4.H), 0.87 - 0.84 (t, j - 7.2 Hz, 6H). MS: Calculated for C m tt22»W$$ = 2649; Found MALD1-TOF m/z = 2672 (M+Na*).

EXAMPLE 3: COMPOUND 3

{00218] Compound 13: Prepared in an analogous m nne from compound 1 and PEG-21 bis-NHS esier.

I0021.9] 5 H NMR (400 MHz, Deuterium Oxide) δ 5.03 (d, </ - 3.9 Hz, 2H), 4.91 (q, J = 6.7 Hz, 2H} 5 4.56 (broad d, J- 8.4 Hz, 2H), 3.98 (broad t, 2H), 3.91-3.86 (ni, 6H), 3.81 ~ 3.79 (ffi, 4B), 3.78 - 3.74 (m, 4H), 3.72 ira, 4H), 3.71 - 3.66 (m, 78H), 3.56 (i, ../ - 5.8 Hz 2H), 3.47 (m 2H) ; 3.35-3.27 (m, Ϊ H), 2.53 -2,49 (t, J= 6.1 Hz H), 2Jl (broad t, 2 H), 2.16 - 2.13 (m, 2H), 2.05 (s, 6H), 1.86 - 1 ,84 (m, 4H), 1.76 ~ 1.65 (m, 4H), i ,63 ~ 1.47 (m, 8H), 1.38 - 1,29 ( , Ί4Ε), 1.27 - 1 .22 Cm, 814), 1.18 - 1.12 (m, 6H), 0.94 - 0.89 (m, 4H), 0.87 - 0.84 (t, J™ 7.2 Hz, 6H), MS: 2473.3; Found MALDi-TOF mfz = 2496 (M+Na*).

EXAMPLE 4: Compound 1 f0fi22©| Compound 14: Prepared in an analogous manner from com ound 1 and PEG- !

(00221] } H MMR (400 MHz, Deuterium Oxide) δ 5.06 (d, J= 4.1 Hz, 2H), 4.94 (q, «/ = 6.6 Hz, 2H K 4.56 (broad d, J™ 4 Hz, 2H k 4.02 (Broad s, 2H), 3.94-3.9 to, 6H), 3.84 (m, 2H), 3.80 (m, 4HX 3.76 to, 6H), 3.72 - 3.70 (ra, 50H), 3.59 (broad t, 2H), 3.49 to, 2H) 5 3.38-3.33 (m, 10H), 2.54 (t, J = 6.1 Hz 4H), 2.34 (broad i, 2H), 2.19 - 2.17 (m, 2H), 2.09 (s, 6H), 1.90 - 1.87 (m, 4H), 1.79 - 1.71 Cm, 4H),1.69 - 1.58 (m, 8H), 1 .56 (m, 2H), 1.51 (m, 4H>, 1.43 - 1.36 <m, 4H), 1.35 -1.33(m, 6H), 1.27 - 1 .17 (m, 8H), 1 .00 - 0.91 (m, 4H), 0.90 - 0.88 (t, J^ 7.4 Hz, 6H). MS; Calculated for C^HmHAs :::: 2121.1 Found MALDI-TOF m/z - 2144 {M- i -Na * }.

EXAMPLE 5; Compound 15

|0O222| Compound 15: Prepared in an analogous manner from conipomid 1 and PEG- 10 bis- HS ester.

|ίΜΪ2231 *H NM (400 MHz, Deuterium Oxide) § 5,06 (d, ' = 4,0 Hz, 2H), 4.94 (q, ./= 6.7 Hz, 2H), 4.56 (broad d, ./ = 8.4 Hz, 2H), 4.02 (broad s, 2H), 3.95-3.90 (m, 6H), 3.84 (m, 2H), 3.79 (m, 4H), 3.75 (m, 6H), 3.72 (m, 30H), 3.70 (broad s, I OH), 3.58 (broad t, J- 5,6 Hz 2H), 3.51 (m, 2H), 3.38-3.35 (m, 6H), 3.34-331 (m, 4H>, 2.54 (t, 4H), 2.34 (broad t, 2H), 2.19 - 2.17 (m, 2H), 2,09 (s, 6H), 1 ,90 - 1.87 (m, 4H), 1.79™ 1.66 (m, 4H), 1.63 - 1.55 (m, 8H), 1.53 - 1.49 (m, 2H), 1.41 (¾ J- 12.0 Hz, 4H), 1.37 - 1.32 (m, 8H), 1.27 (broad d, J - 6.6 Hz, 6H) 5 1.24 - .1.17 (ra ; $H), 0,98 - 0.93 (ra, 4H>, 0.90 ~ 0.88 (t, J~ 7.4 H* s 6H). MS;

Calculated for C¾f½oN 6 C :::: 1989.0; Found MALDi-TOF m/z « 2013 (M+Na 'f ).

EXAMPLE 6: Compound 16

100224) CoiMtpoiilid 16: Prepared in an analogous maimer from compouad 1 and FEG-9 bis-NHS ester.

|0022S] Ή NMR (400 M¾. Deuterium Oxide) 3 7.82 (re, 2H), 6.83 id. J - 8.9 ¾ 211 ). 4. 1 (d, ../ 4.0 11/. 21 ), 4.79 (q, 6.7 Bz, 2H), 4.39 (d, J - «..5 ¾ 2H), 3.96 - 3.83 (n% 4H), 3. 1 ( J = 3,0 Hz, 2H) S 3,79 - 3.71 (m, 4H), 3.71 - 3,47 (m, 34H), 3.47 - 3.31 (m, 4H), 3.31 - 3.07 (m, 10H), 2.39 (1 6.1 Hz, 4H), 2.19 (t, J= 12,5 Hz, 2M), 2.03 (broad d, J - 6.8 Hz, 2Η), 1 .93 (s, 6H), 1.73 (broad d, /= 12.5 Hz, 4H), 1.68 - 1 .34 (m, 16H), 1.34 - 1.15 (m, 4H), 1.15 - .91 (in, 14H), 0.91 - 0.65 (m, 10H). MS: Calculated for CwHmN^ ::: 1812.9; Found ES-Negaiive m/z ^ 1 812.8 (M-l).

EXAMPLE 7: Compoimd 17

(ΘΘ226] Compound 17: Prepared in an analogous manner from compoimd 1 and PEG-4 bis-NHS ester. 2271 ¾ ΗΜΕ (400 ΜΗ«, Deuterhim Oxide) δ 4.91 (d, J - 4,0 ¾ 2Η% 4.80 (q, J= 6.7 lb-.. 2Η) 4.40 (broad d, J - 8.4 Hz, 2B), .00 - 3.84 (m, 4H) > 3.82 id, J 3.0 Hz, 2H) S 3.76 (dd, J= 10.6, 3.2 Hz, 2H>, 3,72 - 3.57 (m, I2H), 3.55 (m, J- 3.1 Hz, 14H), 3.42 (m, J - 7.5, 4,5 Hz, 4H), 3.30 - 3,09 (m, lOM), 2.39 (t } = 6.1 Hz, 4H), 2.20 (broad t,.J- 12,6 Hz, 2H), 2.03 (ffl, J- 6.5 Hz, 2H), 1.94 (s, 6H), 1.73 (broad d, J = 12.5 Hz, 4H>, 1.67 - 1.33 (m, 16H), 1.33 ~ 0.93 (m, 20H), 0.89 ~ 0.67 (ra, 10H). MS; Calculated for C*Hi»N«Qs - 1724.9; Found ES-Negative m/z » 1724.8 (M«l ).

EXAMPLE 8; Compound 18

[00228] Compound 18; Prepared in an analogous manner from compound 1 and PEG-2 bis-HHS e ier.

(00229] ! H NMR (400 MHz, Deuierimn Oxide) δ .91 (d, ,/- 4.0 ¾ 2H), 4,79 (q, J- 6.7 Hz, 2H), 4.40 (broad d, J== 8.5 Hz, 2H), 4.01 - 3.84 (m, 4H) 5 3.81 (d, J- 3.0 Hz, 2H), 3.76 (dd, 10.5, 3.2 Hz, 2H), 3.72 - 3.55 (ffl, 14H), 3.52 (s, 4H), 3.42 (m, J - 6.0 Hz, 4H), 3.28 - 3.06 (m, 10H), 2.38 (t, J= 6.1 Hz, 4H), 2.19 (broad t, j= 12.7 Hz, 2H), 2.03 (m, ./= 6.5 Hz, 2H), 1.94 (s, 6H), 1.73 (ro, J = 12.5 Hz, 4H), ί .67 - 1.33 (m, 16H), 1.33 - 0.92 (m, 20H), 0.92 - 0.60 {HI, l OH). MS; Calculated for Ca&sW*. 1636.8: Found E$-Negative m/z * 1636.7 (M-i). EXAMPLE 9: Compound 19 ftM>238] Comp und 19: Prepared i an analogous manner from cornpourid 1 and succinic acid bis- HS ester.

1>Θ231] Hi mm (4G0 MB/ D<mteriurn Oxide) δ 4.91 (d, ~ 4.0 ¾/2H 5 4.80 , - 6,8 Hz, 2H), 4.41 (broad d, J~- 8.6 Hz, 2H), 3,88 (m, 2H), 3.81 -3,74 (m, 6H) 5 3.73-3.65 (m, 6Ή), 3.64-3.56 (m, 6H), 3.45 (broad t 2H), 3.33 (broad d, J= 9.9 Hz, 2H) 5 3.20 (m, J- i 1.4, 10.3 Hz, lOH). 2.39 (s, 4H), 2.19 12.8 Hz, 2H) ( 2.02 (m, 2H), 1.94 (s, 6H), 1.84 -

1.69 (m, 4H), 1.51 (m, J = 65.3, 30.1 , 14.0 Hz, 14H), 1.26 (q, ./ = 12.5 Hz, 6H), 1 ,09 (m, J = 28,4, 8,7 Hz, 14H), 0.94 - 0.64 (ni, 10H). MS: Calculated for C ? 2H S 2<)N 6 Oai - 1548,8; Found ES- egative m& = 1548,67 (M-I),

EXAMPLE 10: Compous 00232] Compound 20: A solution of compound 15 (12.4 tug, 6,23 μιηο β) and ΌΪΡΕΑ (1 1 μΐ., 62.3 μ,ηΐοΐβ,) in anhydrous DMF (0.2 mL) was cooled to (fC and TBTU (12 mg, 37,8 pmole) was added. The resulting solution was stirred for 10 minute. Azetidine (8.4 μΙ. ; 124.6 μηιοΐβ,) was added and the resulting solution was stirred for Ih at room temperatore. The reaction mixture was concentrated under high, vacuum, and. the residu was purified by HPLC. The product portio was collected and evaporated, re-dissolved in minimum amount of distilled water then iyophilized overnight to give compound 29 as a white solid (6.3 mg, 49%).

(00233) ! H NMR (400 MHz, Deuterium Oxide) 3 8.32 (s, 2i¾ 8.23 (d, J - 9.5 Hz, 2H), 4.92 (broad d, 2H), 4.79 (q, J = 6.7 Hz, 2H), 4.42 (m, 2H), 4.23 (q, J= 7.8 Hz, 2H), 4.14 (q, J - 7.8 Hz, 2H), 4.06 ~ 3.79 (m, 6H) ? 3.76 (dd, J~ 10.5 Hz, 2H), 3.66 (m, J ::: 15, i, 13.8, 8.6 Hz, 8H), 3.57 (m, J- 8.0 Hz, 46H), 3.41 (m, 4H), 3.21 (m, J™ 14.4, 12.2 Hz, 10H), 2.45 - 2.34 (t, 4H), 2.22 <m, J- 12.9 Hz, 6H), 2.02 (m, 2H) 5 i .94 (s, 6H), ! ,74 (broad d, J ~ 12.2 Hz, 4H), 1.68 - .1.33 (m, 14H), 1.26 (m, J = . ί Hz, 6H), 1.15 - 0.95 (m, 16H), 0.95 - 0.64 (m, 10H). MS: Calculated for CygHneNsOj* = 2067; Found ES~Negative m/z = 1033.6 «M~l)/2).

[00234] The following compounds were prepared in aa aaalogous maimer.

EXAMPLE 1 1 ; Compound 21

[00235] Compound 21 : Prepared in an analogous manner from compound 15 and dimetliylaraine.

[00236] ¾ NMR (400 MHz, Deuterium Oxide) δ 8,33 (s, 6H), 4.93 (broad s, 2H), 4.80 (q, 2B), 4.42 (broad d, J = 9.9 Hz, 4H), 3.89 (broad s, 2B), 3.77 (dd, J- 10.9 Hz, 2B), 3.74 - 3.49 (m, 54H), 3.42 (Broad s, 4H>, 3.21 (m, « - 14.5, 12.4 Hz, J OH), 2.95 (s, 6H), 2.83 (s. 6H1 2.41 (broad t, 4H), 2,21 (broad i, 2H), 2.05 (m, 2H>, ! .97 (s, 6H), 1.73 (m, 6H), 1.67 - ! .36 (m, J 2H), 1.36 - 0.96 (m, 20H), 0.80 (d, J= 38.2 ¾ U)H). MS: Calculated for - 2043.0; Found ES-Negative m/z - 1066.8 (( +formic aeid-l)/2).

EXAMPLE 12: Compound 22 00237} Compound 22; Prepared in an analogous manner from compound 1.2 and

( 238) ¾ NMR (400 MHz, Deuterium Oxide) 8 .33 (s, 2H), 4.92 (d, </ - 4.0 Hz, 2H), 4,79 (q, ,/= 6.6 ffe, 2H), 4,42 (Broad d, J = 8,6 Hz, 2H), 4.24 (q, 8.7 Hz, 2H), 4, 15 (q„ ./ = 8.6 Hz, 2H), 3.96 (m, J - 25.2, 9.1 H¾ 4H), 3.86 (broad s, 2H 3.77 (dd ( 10.6, 3.1 Bz, 2H), 3,73 - 3.47 (m, 1 14H), 3.42 (m, J= 7.8, 4.6 Hz, 4H), 3.20 (m, J= 22.8, 8.6 Hz, lOH), 2.41 (t, J= 6.1 Hz, 4H), 2,35 - 2.13 (m, 6H), 2.04 (m, J = 10.8 Hz, 2H), 1.95 (s, 6H), 1.75 (broad d, /- 12.7 Hz, 4H), 1.68 - 1.35 (m, Ϊ6Ε), 1.35 - 0.94 (n% 20H), 0.94 - 0.67 (m, 10H). MS: Calculated for C m r½oNsO» - 2727.5; Found ES-Negative m/z = 1409.3 ((M+forraic. acid-l}/2}.

EXAMPLE 13: Compound 23

[00239] Compound 23: Prepared in an analogous manner from compound 17 and azeiidirie.

[08248] ¾ NMR (400 MHz, Deuterium Oxide) 3 8,28 (broad s, 2H), 8,23 (broad d, 2H), 4.91 (d, J = 4.0 Hz, 2H), 4.78 (q, 7.4, 6.9 Hz, 2H), 4.41 (broad d,J « 8.5 Hz, 2H), 4.23 (q, ,/ = 8.7 ¾ 2H), 4.34 (q, 8.8 Hz, 2H), 4.04 - 3.80 (m, 8H), 3.76 (dd, ,/= 10.6, 3.2 Hz, 2H), 3,72 - 3.58 (m, 16H), 3,55 (d, J = 3.0 Hz, 12H), 3,41 (m, J = 7,7, 4.4 Hz, 4H), 3.30 - 3.10 (m, IOH), 2.40 (1, /= 6.1 Hz, 4H), 2.34 - 2. Ϊ2 (ra, 6H), 2.03 (m, J= 7J Hz, 2H), ί .94 (s, 6H), 1.74 (broad d, J = 12.7 Hz, 4H), 1 ,67 - 1 ,33 (m, 14H), 1 .33 - 1.16 (m, 8H), 1.16 - 0,95 (m, 14H), 0.95 - 0.64 (ra, IOH). MS: Calculated for C^H u & » n = 1803.0; Found ES-Positive m z 1826.8 (M+Na '* }.

EXAMPLE 14; Compound 24

Compound.24: Prepared in an analogous manner from compound 16 and

100242] Ή NMR (400 MHz, Deuterium Oxide) δ 4.92 (d, /= 4.0 Hz, 2H), 4.79 (q, J « 6.6 Hz, 2H), 4.42 (m, 2H), 4.24 (q, 8.7 Hz, 2H) 5 4.14 (q, 8.4 Hz, 2H), 3.96 (m, 24.9, 8.9 Hz, 8H), 3.80 - 3.48 (m, 36H), 3.42 (m, 7.7, 4.4 Hz, 4H), 3.19 (m, J^ 23.4, 8.5 Hz, 1 OH), 2,40 (I, J = 6.1 Hz, 4H), 2.32 - 2, 10 <tn, 8H), 2,02 (m, 2H), 1.94 (s, 6H), 1.74 (broad d„ ,/ = 12.5 Hz, 4H), 1 ,67 - 1 ,34 (m, 14H), i .24 (m, J = 1 i .2 Hz, 8H), 1.16 - 0,94 (m, 14H), 1935.9 (M+formic acid-1).

EXAMPLE 15: Compound 25

(60243] Compoand 25: Prepared in an analogous maimer from compoun 18· and azetidme.

[ΘΘ2 ] 1 H NMR (400 Mrfct, Deuterium Oxide) δ 8.23 (d, / - 9.6 Hz, 2H), 4.91 <d, J = 4.0 Hz, 2H), 4.78 (q, J - 6.7 ¾ 2H>, 4.41 (broad d, J 8.5 H , 2H), 4.23 (q, j - 8.6 Hz, 2H) 5 4.14 (q, J- 8.7 Hz, 2H), 3.95 (m, J- 24.6, S.8 Hz, 8M), 3.76 {dd, J= 10.6, 3.2 Hz, 2H), 3.72 - 3.55 (m, 14H), 3.53 is, 4H), 3.41 (m, </ - 7.7, 4.4 Hz, 4H), 3. 19 (m, .7- 13.5, 10.9 Hz, 12H), 2.39 (t, J = 6.1 Hz, 4H), 2.21 (m, ./ = 16.L 8.8 Hz, 6H), 2.02 (m, 2H), 1.94 (s, 6H), 1.74

{broad d, J - 12.4 Hz, 4H), .1.67 - 1.33 (m, 14H), 1.33 - 0.93 (m, 22H}, 0.93 - 0.62 (m, 10H). MS: Calculated for 1737.8 ( .+Na*).

EXAMPLE 16: Compound 27

(60245) ' .Compound 27; To a mkiure of compound 2 (72 mg. 91 μιπο ί©) and compound

2 (azido-PEG3-az.ide) (9.3 mg, 38 μηιοΐε) in deiaftized water (2 mL) was added a solution of CuSOi-THPTA (0.04M) (0.5 mL) and sodium ascorbaie (3 mg, 0.19 mmoie

successively. The reactio mixture was. stirred .overnight at room temperature. The reaction mix ture was concentrated under high vacuum and the residue was purified by HPLC. The product was tyophitized overnight to give compound 27 as a white solid (3.0 mg, 4%).

27

[002461 1 H NMR (400 MHz, Deuterium Oxide) δ 8.27 (s, 2H), 8,22 (s, 2H), 4.88 id, J - 4.0 Hz, 2H , 4.78 <q, J = 6.8 H , 2H>, 4.53 (t, J - 4.9 Hz, 4H), 4.39 (broad d, J = 8.6 Hz, 2H), 3.94 - 3.80 (m, 8H), 3.80- 3.72 (m, 4H), 3.72 - 3.64 (m, 4H), 3.60 (m, J - 5. Hz, 4H), 3.54 - 3.31 (in, 18H), 3.31 - 3.09 (m, 4H), 2.16 (broad t J - 12.6 Hz, 2H), 2.01 (m, J - 7.5 Hz, 2H), 1.90 (s, 6H), \ .80 - 1.30 (m, 20H), 1.22 (m, J - 1 1.9 Hz, 2H>, i .I6 - .87 (m, 18H), 0.78 (m, J .= 23.1, 10.9 Hz, 4H), 0.63 (i J - 7,3 Hz, 6H), MS: Calculated for

C82H 134 12033 « 1814.9; Found ES-Negative m z = 1814,7 ( -l).

[00247] The following compounds were prepared in an analogous manner;

EXAMPLE 17; Compound 28

[00248] Compound 28; Prepared in an analogous manner from compoimd 2 and azido- PEG2-azide.

28 [0Θ249] *H NM (400 MHz, Deuterium Oxide) § 8.23 ($, 2H), 4.87 (d, J = 4,0 Hz, 2Ή), 4.7? (q, J = 6.9 Hz, 2H), 4.50 (t, J= 4.9 Hz, 4H), 4.37 (broad d, J= 8.6 Hz, 2H), 3.87 (broad d, J- 5.9 Hz, 4H), 3.82 ~ 3,71 (m, 8H), 3.71 - 3.63 (m, 4H), 3.63 ~ 3.53 (ra, 4H), 3.50 (m, 6E), 3,46 ···· 3.32 (m, 8H), 3.32 - 3.23 (ra, 2H), 3.23 ···· 3.09 (ra ; 2H), 2.17 (broad t, - 12.8 Hz, 2H), 2.10 - 1.97 (m, 2H), 1.89 (s, 6E), 1.82 - 1.30 (m, 20H), 1.21 id, . J = 12.1 Hz, 4H), 1.16 - 0.87 (m, 1 HL 0.79 (dt, J - 22.3, 10.7 Hz, 4H>, 0.62 (t, J- 7.4 Hz, 6H). MS:

Calculated for€¾ιί½οΝ !2 0¾ - 1770.8; Found ES-Negative /« ¾ - 1769.7 (M-l >.

EXAMPLE 18: Compound 29

[00250] Compound 29: To & solution of compound 7 (46 mg, 56 mole) arid compound 26 (azido-FEG3-azide) (5.6 rag, 23 μ-mole) in a solution of MeOH (3 mL) and distilled water (0.3 mL) was added a solution of CuSG TBPTA (0.04 ) (0.3 mL) and sodium ascorbate (23 mg, 0.12 mraote) successively. The .resultmg solution was stirred ■' overnight at room temperature. To complete the reaction, another set of catalyst was added and the reaction was continued additional 6 hrs. After the reaction was completed, the solution was concenti ' ateti under high vacuum and the residue was purified b HPLC. The product portion was collected and evaporated, re-dissolved in minimum amount of distilled water then lyopMiized

overnight to give compound 29 as a white solid (25.2 mg, 13.3 .umole, 57%).

[00251] l H NMR. (400 MHz, Deuterium- Oxide) S 8.28 (s, 2H), 4,88 (d, ,/ - 4,0 Hz, 2H), 4.77 (q, J 6.8 H¾ 2H), 4.53 (t, J - 4.8 x, 4H), 4.38 (broad d, 2H), 4.23 (q, J - 7,7 Hz, 2B), 4.13 (q, J= 8.4 Hz, 2H) S 4.07 - 3,87 (m, 6H), 3.82 (t, J 4.9 Hz, 4H), 3.79 - 3.63 (m, 8H), 3.63 - 3.55 (m, 6H), 3.55 - 3.32 (m, 14H), 3.32 - 3.10 (m, 4H), 2.33 - 2.08 (m, 8H), 2.02 (m, 2H1 1,89 ($, % 1. 1 - J .31 (m, 18H), 1.22 (m, /= 11.6 Hz, 6fi), 1.17 » 0,90 (m, 14H), 0.90 - 0.68 (m, 4H), 0.63 (t, J= 7.3 Hz, 6H). MS: Calculated for C^H^ ^O^ = 1893.0; Found ES-Posilive m/z = 969.5 (M/2+Na .

(00252} The following compoimds were prepared i an analogous manner:

EXAMPLE 1 : Compound 30

|i)0253} Compound 30 Prepared in an analogous manner from compound 7 and azido- PEG5~a ide.

(00254) Ή NMR (400 MHz, Deuterium Oxide) δ 8.33 (s s 2H), 4.88 {d, ./ - 3.9 Bz, 2H), 4.77 ( , </ = 6.8 Hz, 2H), 4.55 (L J = 5.0 Hz, 4H), 4.39 (m, 2H), 4.22 (q, J = 8.2 11¾ 2H), 4.13 (q, J- 8.7 Hz, 2H , 4.00 (broad d, J 9.9 Hz, 2H), 3.93 (q, J 7.7 Hz, 4R), 3.85: St. ,/ 5.0 Hz, 4B), 3.74 (dd, J~ 10.5, 3.2 Hz, 2H), 3.70 (broad d, J = 3.0 Hz, 2H), 3.6 - 3.62 (m, 4H) ; , 3.59 (m, J ~ 7.7 Hz, 6H), 3.53 (m, J - 5.6 Hz, 2H), 3.47 (m, J- 11.4, 4.1 Hz, 12H), 3.43 - 3.31 (m, 6H), 3.31 - 3.22 <m, 2H>, 3.17 (i, J= 9.7 Hz, 2H), 2.20 (m, 14.0 Hz, 8H), 2.01 (m, J = 10.3 Hz, 2H), 1 ,90 (s, 6H), 1 ,75 - 1,31 (m, 18H), 1.22 (rn, ./- 12.1 Hz, 6H), 1.16- 0. 1 (m, 14H), 0.91 - 0.69 (m, 4H), 0,63 (t, ,/ = 7.3 Hz, 6H). MS: Calculated for

C^H^NHO^ = 1981.0; Found ES-Positive m/z ^ 101 .6 (M/2+Na * ).

EXAMPLE 20: Compound 3 !

{002551 Compound 31: To a solution of compound 2 (30 mg, 38 umole) and compound 9 (46 mg, 57 μηιοίε) in distilled water (2 mL) was added a solution of CuSC* 4 -THPTA (0.04M) (0.2 ml.) and sodium ascorbate (1.5 mg, 7.6 pmoie) successively. The resulting solution was stirred for 4 hrs at room temperature. The solution was concentrated under high vacuum and the residue was purified b HFLC. The product orti n was -collected and evaporated, re- dissolved in minimum amount of distilled water then lyophilteed overnight to give compound 31 as a white solid (3.5 nig, 6%).

[00256} } H NMR (400 MHz, Deuterium Oxide) 5 8.39 (s, i.H), 5.23 (s, 2H), 4.97 (t, J ~ 4.5 Hz, 2H), 4.85 (m, 2H), 4.45 (broad t, 2H), 3.94 (ra, 2H), 3.91 - 3.78 (m, 6H), 3.77 - 3.62 (m, 12H), 3,61 - 3,40 (m, 8H), 3.40 - 3.16 (m, 8H), 2.24 (m, ,/= 12.0 Hz, 2H), 2.09 (m, 2H), 1.98 (two s : , 6H : ; 1.89 - ! .37 (m, 20H), 1.36™ ! .24 (m 4H), 1.23 ~ 0.94 (ro, IRE), 0.93 - 0.77 (m, 4H), 0,71 (t, J 7.2 Hz, 6H). MS: Calculated for C 73 H } isNsC o « 16 1.8; Found ES- Negaiive m/z = 1600,5 (M-H).

EXAMPLE 2 i ; Compound 32

[ΘΘ257] Compound 32 : To a solution of compound 1 (25 mg, 34 umole) and

carbouyldiimidazok (2.3 mg, 14 μη?οίβ) in anhydrous DMF (1 mL) was added 0ΙΡΒΑ (20 μΕ), The resulting solution was stirred overnight at room temperature under an ?

atmosphere. The reaction mixture was concentrated under high vacuum and the residue was purified by HFLC, The product portion was collected and evaporated, re-dissolved in minimum amount of distilled water then lyophilized overnight to giv compound 3 as a white solid (1.6 mg, 8%).

(00258} Compound 32 (Alternative Synthesis): To a solution of compound 1 (0.77 g, 1 ,04 mmoie) in anhydrous DMSO (3 mL) was added bis( ?-«itrophenyi) carbonate (0.15 g. 0.49 mole) (3 ffiL), The reaction mixture was stirred overnight at 40 °C. The reaction mixture was lyophilized to dryness. The residue was purified by reverse phase C-18 column chromatography eluting with a solution of water/MeOH (gradient change from 9/1 to 1/9 v/V). The product portion was concentrated and lyophiiteed to give the desired product as a white solid (0.47 g, 0.31 mmole, 48%),

[00259] 'H M (400 MHz,■Deuterium Oxide) S 4.92 {¾ J- 4.0 i¾ 2¾ 481 6.7 Hz, 2H) ; 4.42 (broad d, J~ 8.5 2H), 3.88 (m, 2H), 3.84 - 3.74 (TO, 6B), 3,73 - 3.56 (m, 12H).3.45 (t J - 5.9 Hz, 2H), 3.36 (broad d t J = 10.1 Hz, 2H), 3:29 - 3.00 (m, 12¾ 2.23 (broad t, J= 12.7 Hz, 2H) t 2,05 (m, 2H), i .95 Cs, 6Ή), 1.75 (broad d, 7 » 1 .5 Hz, 4H), 1.69 ~ 1.35 (m, 18H), 1.35 - U6 (m f 6H), 1.15 - .92 (m, 16 ' H), 0.91 - 0.62 (ra, i:2H); MS:

Calculated for C<sH ] ]6 N 6 C¾ = 1492.7; Found ES-Negative = 1491.5 (M-H).

EXAMPLE 22; intermediate 35

[00260] Cojnponnd 35: A solution of L -Lysine (O ' Bn ester) (0.15 g, 0.49 o!e) in anhydrous DMF (3 mL) was cooled to 0 "C and DIPEA (0.35 mL, 2.0 mmole) was added. The solution was stirred for 10 mm... This solution, was added t a solution fKj-PECl-NHS ester (compound 34} (0.30 g, .1.16 mrnoie) over a 5 minute period followed by a catalytic amount of DMAP (20 mg). The resulting -solution was stirred Overnight while temperature was gradually increased to room temperature. The solution was concentrated and the residue was dried under high vacuum for 30 min to dryness, then directly purified by Combi-flasli (EiOAc MeOH, EtOAc only - 2/1, v/y). The product portion was collected and evaporated. then dried unde high vacuum to give compound 35 as a light yellow gel (0.25 g„ 0,48 nimok 98%). MS: Calculated (C23H34N806, 51 .2), ES- positive (519.2, M+l, 541.2 M+ a).

35

1002611 *H NMR (400 MHz, Methanol-^) 8 7.4? - 7.22 (ui, 5H>, 5.31 - 5.03 fdd, 2B%. 4.45 (dd, J -.8.7, S.2 HK, . IH), -3.S6 - 3.66 im, 4H) f 3.63. (q, J -4.9 R¾ 4H), 3,45 - 3.24 (m s 7H), 3, 17 (id, J- 6.9, .9 Hz, 2H), 2.63 - 2.48 (m, 2H), 2.45 (t, 6.1 Hz, 2H), 1.86· (did, ./ - 13.3, 8.0, 5.2 Hz, ! H), 1.80 - 1.63 (in, 1H), 1.63 - .1.45 (m, 2H), 1.39 (m, 2H).

EXAMPLE 23: fotermedkie 36

{60262 j Compound 36: Prepared in an analogous manner From compoiind 33 and azido- PEG5-NES ester in 58% vield.

36

[00263] ¾ NMR (400 MHz, Methanol-^} S 7.48 - 7.26 (m, 5H), 5.29 - 5.09 (dd, 2H), 4.45 (dd, J ---- 8.8, 5.2 .Hz, IH), 3.81 - 3.55 (m, . 41 H), 3.43 - 3.36 (m, 5H), 3.33 (p, = .1.7 H*, I2H), 3.17 ft, J 7.0 life, 21 S h 2.6.1 - 2.49 (M, 2H), 2.44 (i . J ~ 6. 1 Hz, 2H), 1.95 - 1 .80 (m.. I H), 1.80 - L66 (m, 1H), .1 .61 - 1.46 (m, 2H), 1,46 - 1,31 (m, 3H).

EXAMPLE 24; Compound 37

{ΘΘ264) Compound 37: To a solution of compound 35 (24 mg, 4 μηιοΐβ) and compound 2 (94 mg, 0.12 mrao!e) in of MeOH (1 raL) arid water (1 mL) was added a solution of CuSOrTHPTA (0.04M.0.23 mL, 20 umole) and sodium ascorbale (2.7 mg, 14 μιηοΐβ) successively. The resulting solution was stirred for 3 days at room temperature. The solution was concentrated under reduced pressure and the mixture of mono- and di-coiipled products was separated by C-18 column. (water/MeOH, water only ~ ¼, v/v) To complete the reaction, this niixtare was re-subjected to the reaction conditions as described above overnight at 40 °C The reaction solution was then dialyzed against water with dialysis tube MWCO KMX) while distilled water was changed every 6 hours. The aqueous solution in the tube was collected and iyophiiked to give compound 37 as a white solid (53 trig, 55% yield).

[00265] ¾ R (400 MHz, Deuterium Oxide) 3 8,27 (broad two s » 2H), 7.27 (m, 5H), 5.05 (broad s, 2H), 4.92 (broad s, 2H), 4.81 (m, 2H), 4.62 - 4.28 (m, 6H), 4.20. (m, 1H), 4.09 - 3.55 (m, 26H), 3.55 - 3 JO (m, 13H), 2.93 (broad t, 2H), 2.42 (broad t, 2H), 2. 1 (broad t, 2H), 2.20 (m, J - 12,6 Hz, 2H), 2.06 (m, 4H), 1 ,95 (m, iOH), i ,84 ~ 1.36 (m, 12H), 1.35 ~ 0.91 (m, 12H), 0.91 - 0.72 (m, 10.), 0,71. - 0.60 (broad t, . 8H} MS: Calculated (C*7Hm i 4 <¼ 2089,0), ES-Negative (20WX M S 1042.9 /2-I).

EXAMPLE 2.5: Compound

|00266j Com ound 38 : A solution of compound 37 (13 mg, 6.2 pmole) in anhydrous MeQH (2 mL) was hydrogenated in the presence of Pd(OH)i ( 10 mg) for 2hrs a room temperature. The solution was filtered through a Celtte pad and the filtrate was concentrated. The crude product was purifie by HPLC, The product portion was collected, evaporated, then !yophilized overnight to give compound 38 as a white solid (4,5 mg, 36% yield).

[00267] *H NMR (400 MHz, Deuterium Oxide) § 8.28 (two s, 2H), 4.89 (d, J « 4.0 Hz,

2H), 4.79 (q, J : ™ 6.7 Hz, 2H>, 4.54 (q, J™ 4.6 Hz, 5H>, 4.40 <d, J - 8.6 ¾ 2H) 5 3.98 (dd, ./ " = 8.5, 4.7 Hz, 1H), 3.95 - 3.79 (m, 6H) S 3,78 ·- 3,74 (m, SH), 3,73 - 3.67 (m, 6H), 3.66 ·- 3.55 (in, 13H), 3.54 - 3.32 (m, 1 1 H), 3.31 - 3.24 (m, 2H), 3.18 (t, J = 9.7 Hz, 2H), 2.92 (t, J= 6.9 Hz, 2H} ? 2.49 - 2.33 (m, 2H), 2.30 (t /=== 5.8 Hz, 2H), 2.19 (broad t, J= 12.6 Hz, 2H), 2.1 1 - 1.98 (η\ 2Ή), 1.92 (d ? J - 3.1 Hz, 6H), 1.79 - 1.33 (m, 24E), ! .23 (ro ? 3H), L 18 - 0.89. (m, 20H 0.88 - 0.69 (m, 5H), 0.64 (t 7.4 Hz, 6H) MS: Calculated (C^H^N^O^, 1999.0), ES-Negaiive (1219.2 M/2- 1 ).

EXAMPLE 26: Compound 39 ΘΘ26& j Compound 39: Compound 39 was prepared in 52% yield using an analogous procedure starting from compound 2 and compound 36.

I00269J H NMR (400 MHz, Deuterium Oxide) 5 8,35 (s, 2H), 7,41 - 7,20 (m, 5H), 5.21 - 5.01 (dd, 2H), 4.92 (4 4.0 Hz, 2H), 4.81 (ra, J ~ 6.8 Hz, 2H), 4.58 (t, J™ 4.9 Hz, 4H), 4.42 (d, ./ ' = 8.6 Hz, 2H), 4.35 - 4,21 (in, IB), 3.88 (m, J~ 5.0 Hz, 6H), 3.84 - 3.75 (m, 5H), 3.74 - 3.70 (m, 4H), 3.69 ~ 3.59 (ra, 1 1 H), 3.58 - 3.44 (m, 36H), 3.43 - 3.34 (m, 6H), 3.33 - 3.24 (m, 3H), 3.20 (t, / == 9.7 Hz, 2H), 3.03 (t J- 6.8 Hz, 2H), 2.46 (t, J ~ 6.1 Hz, 2H), 2.37 (t, J. = 6,0 f¾ 2H), 2,20 (broad t, J ~ 12,3 H¾ 2H), 2,05 (m, 2H), 1.93 (s, 6H), 1.82 - 1.33 (m, 24H), 1 .32 - J .18 (7H), 1.17 - 0.91 (m, 17H) ; 0.90™ 0.72 (m, 5H), 0.6? (t s ,/= 7.3 H¾, 6H) MS: Calculated (CIUHIMNIJOU, 2441.2), ES-Negative 0219.2 M/2- ).

EXAMPLE 27; Compound 40 00270} Compound 40; Compound 46 was prepared in 26% yield using an analogous procedure startin from compound 39.

[00271 ] Ή NMR (400 MHz, Deuterium Oxide) S 8.36 (two ■■$, 2i¾ 4,90 (d, J— 3.9 ¾· 2H), 4.S0 (q, J ~ 6J Hz, 2H), 4.58 (t, J = 4.9 Hz, 5H), 4.41 id, J- 8,6 Hz, 2H), 4.05 (dd, J = 8.5, 4.7 Hz, IH), 3.98 - 3.82 (ra, 5H), 3.81 - 3.72 (ra, 5H), 3.72™ 3.5 (m, I IH), 3.59 - 3.32 (m, 34H), 3,32 - 3, 1 1 (m, 5H), 3.06 (t, J= 6.9 Hz, 2H), 2,57 ~ 2.42 (m, 2H), 2.38 (t, «7= 6, 1 Hz, 2H), 2.20 {broad t, J~ 12.2 Hz, 2H), 2.04 (m, 2H), 1.92 Cs, 6H), 1.78 - 1 ,32 (m, 20H), 1.32 - 0.88 (m, 24H), 0,89 - 0.70 (m, 5H), 0.66 (i, J = 7,3 Hz, 6H) MS Calculated

C S(½ H t 7sN l4 04 , 2351.2), ES- negative (1 73.9 M/2-1, 782,3, M/3-1 ).

EXAMPLE 28; Compound 42

|002?2{ Compound 42: A solution of compound 41 (described in J ACS, 2002, 124(47), 14085) (22 rag, 49 μηιοΐβ) and D1FEA (28 μΕ, 163 μοιοίε) in anhydrous DMF (0.3 mh) was cooled to ( C and HATU (62 mg, 163 μπιοΐβ) was added. The solution was stirred for 30 minutes. This solution was added to a solution of compound 1 (0.12 g, 1 3 pmole) over a 5 mitt, period. The resulting solution was stirred overnight. The reaction solution was dialyzed against water with dialysis tribe MWCO 1000 while cfistilied water was changed every 6 hours. The aqueous solution in the tube was collected and lyophiiized overnight to give compound 42 as a white solid (69 mg, 54%).

- ioo - 00273J Ή NMR (400 H¾ Methanol-^,) S 4.85 (ra, 6E), 4.52 (broad s, 3B), 3.75 (M, J = 1 1.1 Hz, 15H), 3.69 - 3.52 ( s 12H), 3.38 (broad t, J = 1.7 Hz, 3H)„ 3.37 - 3.06 (m, 45H, partially hidden by MeOH), 2.67 (m s 6H), 2.52 - 2,34 (ra, 15H), 2.15 (broad t s M 2.08 - 1.96 (m, 3H), 1.88 (m, 12H), 1.73 (m, 3H), 1.70 - 1.37 (m, 12H), 1.36 - 0.98 (m 5 36H> 5 0.93 - 0.71 (m, / » 2592.3; Found ES- Negative m/z = 1295. (M/2-H).

EXAMPLE 29; Compound 44

(ΘΘ274) Compound 44: A solution of tetravalent PEG-active ester (Average MW ~ 20 76, 0.5 g, 0.24 mraoie) in DMSO (5 mL) was added a solution of compound 1 (1.4 g, ϊ .93 mmoie) and DIPEA (0.5 mL) in distilled water (10 mL) over 1 fir period at room temperature. Th resulting solution was stirred for 3 days under the same condition. The reaction solution was dialy ed against water with dialysis tube MWCO 1000 while distilled water was changed every 6 hours. The aqueous solution m the tube was collected and 1 yophilized overnight to give compound 44 (average chain length in) - 110) as a white solid (0.67 g, 0.15 mmoie, 63%).

44 [W27S] *H NMR (400 MHz, Demer um Oxide) § 4.92 (d, ' = 4,0 Hz, 4H), 4.81 (d, ·/= 6.8 ' H¾, 4H), 4.42 (d, ./ = 7.8 Hz, 4H), 3,96 (s, 8H), 3,78 (ra, 12H), 3.74 - 3.50 (m, 1.88H), 3.42 - 3.34(m, 12H), 3.33 - 3.16 (m, 8H), 3.10 (¾ J= 7.4 Hz, 4H), 2.37 -2.14 (m, 4H), 2,05 (m, 4H), 1.96 (s, 12H), 1.75 (m, SH), 1.70 - 1.33 (m, 8H).

EXAMPLE 30: Compound 45 f 06276] Compound 45: A solution ofconipouud 32 (300 nig, 0.2 rnmole) and DIPEA (0.2 mL, 1,0 mmole) in anhydrous DMF (15 mL) was cooled to 0 °C. TBTU (200 rag, 0,6 nimole) was added. The resulting solution was stirred for 3 is at room temperature. Azetidme (4.0 mL, 60.0 mraol) was added. The solution was transferred to a. sealed tube and stirred overnight at 55 f, C. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was partially purified by chromatography using the Combi- flash system and elating with EtOAe/MeOH/water (5/5/1, v/v/v). The .crude product was de-salted using a C-l S column (wster/MeOH, 9/1— 1/9, v/v). The pure product was lyophiilzed to afford a white solid (0.37 g, 2.35 mraole, quantitative).

(00277] ! H NMR (400 MHz, Deuterium Oxide) δ 4.93 (broad s, 1 H), 4.88 - 4.76 {m, IH), 4.42 (broad s t IH), 4.1 (m, 3H), 3.97 (m, 3H), 3.88 - 3,73 (m, 2H), 3.72-3.54 (m, 6H), 3.42 (m, 2H), 3.29 - 3.00 (m, 6H), 2,67 - 2.49 (m, 0.5H), 2.35 - 2.15 (m, 4.H), 2.14 - 1.98 (fit, IH), 1.94 (s, 3H), 1.75 (broad d, «/ - 12.S Hz, 2H), 1.68 - 1.36 (m, 8H), 1.35 - 1.17 (m, J = 1 1 ,3 Hz, 4H), 1.1 ~ 0.98 (dd, J » 20.5, 9.1 H , 7H), 0.94 - 0,67 (m, ,/ = 32,9, 8.9 Hz, 5H) MS: Calculated. (C75H126M8027, 1570,8), ES-Posmve (1594.5, +Ha; 808.5 (M 2+Na), ES-Negaiive (1569,6, M- l ; 784.4, M/2-ί). EXAMPLE 31

E-SELKCII ACTS VITY - ANALYSIS BY SPR.

[0Θ278] Sur face Plasmon Resonance (SPR) measurements were performed o» a Biacore 100 instrument (GE Healtibcare). A CMS sensor chip (GE Healthcare) was used for the interaction between E-selectin and GMI compound. Anti-human igG (Fc) antibody (GE Healthcare) was immobilized onto the chip by amine coupling according to the

manufacturer^ instructions. In. brief, after a 7~min injection (flow rate of 5 μί/mm) of 1 :l mixture of N ' -eihyi~ '-(3-dimethylaminopropy1) carbediiraide hydrochloride and M- hydroxysucc imide, anti-human IgG (Fc) antibody (25 ttg/mj m iOrriM sodium acetate buffer, pH 5.0) was injected using a 6-min injection at 5 μΐ/ram. Remaining activated groups were blocked by injecting I M ethanolamine HCI, pH 8.5. The recombinant human E- seleetin CD63E Fc Chimera (50 pg/mi) (R & D systems) was injected into the experimental cell until 6000-7000 Rli was captured onto the antibody surface. No recombinant human E- selectm/CD63E was injected into the control cell increasin concentrations of GMI compound samples were injected at 30 μΐ/min into both flow cells and ail sensorgrams were recorded against the control. Regeneration of the anti-human IgG (Fc) surface was achieved by injecting 3.M magnesium chloride, followed by 50 mM sodium hydroxide. Data were analyzed using Biacore XI00 evaluation / B!A evaluation 4.1.1 software (GE Healthcare) and Graphad prism 6 software.

E-Se ectift Antagonist Activity of Cotnpotmds

21 18.3

22 2.3

23 2.8

24 2.4

25 3.0

27 8.6

28 3.2

2 3 2

30 2.0

33

32 8.8

37 3.9

38 6.4

39 5.1

40 5.5

42 1.5

44 8.0

45 2.1 (monomer -COjH) 2260 (monomer azetidme) 2600